[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 148
1. Sweetenham JW: Treatment of lymphoblastic lymphoma in adults. Oncology (Williston Park); 2009 Nov 15;23(12):1015-20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lymphoblastic lymphoma in adults.
  • Lymphoblastic lymphoma is a rare disease in adults, primarily affecting patients in their late teens and early 20s.
  • Optimal treatment strategies have been slow to emerge because of the rarity of this disease and the variable distinction in the clinical literature between this condition and acute lymphoblastic leukemia.
  • Although these two conditions are now regarded as a single entity in the WHO Classification of Lymphoid Neoplasms, treatment approaches have developed separately, and recent molecular data suggest that there may be important biologic differences between these conditions that may justify a different treatment approach.
  • Most published data support the use of intensive multiagent chemotherapy induction followed by a consolidation and maintenance phase.
  • Optimal consolidation remains unclear, although there is no clear role of stem cell transplantation after intensive remission induction therapy based on current evidence.
  • Emerging molecular data have identified potential new therapeutic targets with supporting preclinical data.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Neoplasms / therapy. Central Nervous System Neoplasms / therapy. Disease-Free Survival. Humans. Mediastinal Neoplasms / therapy. Recurrence. Stem Cell Transplantation

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Oncology (Williston Park). 2009 Nov 15;23(12):1020, 1026 [20017284.001]
  • (PMID = 20017283.001).
  • [ISSN] 0890-9091
  • [Journal-full-title] Oncology (Williston Park, N.Y.)
  • [ISO-abbreviation] Oncology (Williston Park, N.Y.)
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 33
  •  go-up   go-down


2. Prades JM, Alaani A, Mosnier JF, Dumollard JM, Martin C: Granulocytic sarcoma of the nasal cavity. Rhinology; 2002 Sep;40(3):159-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Granulocytic sarcoma (GS) is a rare localised tumour of malignant myeloid precursor cells occurring at an extramedullary site.
  • It is usually associated with a myeloproliferative disorder but may be seen preceding the onset of leukemia.
  • Extracranial GS may occur virtually anywhere in the body and may be easily confused with large cell and lymphoblastic lymphoma.
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Biopsy, Needle. Bone Marrow Transplantation. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Immunohistochemistry. Risk Assessment. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Nasal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12357718.001).
  • [ISSN] 0300-0729
  • [Journal-full-title] Rhinology
  • [ISO-abbreviation] Rhinology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


3. Iyengar P, Ismiil N, Deodhare S: Precursor B-cell lymphoblastic lymphoma of the ovaries: an immunohistochemical study and review of the literature. Int J Gynecol Pathol; 2004 Apr;23(2):193-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma of the ovaries: an immunohistochemical study and review of the literature.
  • There was no evidence of extraovarian tumor at the time of the operation.
  • A diagnosis of precursor B cell lymphoblastic lymphoma was established by histologic examination, immunohistochemical staining, and molecular analysis.
  • After a 6-month follow-up, there was evidence of focal bony involvement that improved after chemotherapy.
  • Although non-Hodgkin's lymphoma may involve the female genital tract, particularly the ovaries, primary ovarian lymphoma is rare and its definition controversial.
  • To the best of our knowledge, this is only the third reported case of a primary lymphoblastic lymphoma of the ovary.
  • [MeSH-major] Lymphoma, B-Cell / metabolism. Ovarian Neoplasms / metabolism. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism
  • [MeSH-minor] Antigens, CD / biosynthesis. Diagnosis, Differential. Female. Humans. Hysterectomy. Immunohistochemistry. Immunophenotyping. Lymphoma, Non-Hodgkin / pathology. Middle Aged. Polymerase Chain Reaction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15084851.001).
  • [ISSN] 0277-1691
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


Advertisement
4. Lones MA, Perkins SL, Sposto R, Tedeschi N, Kadin ME, Kjeldsberg CR, Wilson JF, Zwick DL, Cairo MS: Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report. J Clin Oncol; 2002 May 1;20(9):2293-301
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-Hodgkin's lymphoma arising in bone in children and adolescents is associated with an excellent outcome: a Children's Cancer Group report.
  • PURPOSE: Non-Hodgkin's lymphoma (NHL) arising in bone is a heterogeneous histologic type of NHL that includes large-cell lymphoma, lymphoblastic lymphoma, and small noncleaved-cell lymphoma.
  • EFS in 17 patients treated with chemotherapy and radiation was 70.1% +/- 11.2%, and EFS in 14 patients treated with chemotherapy without radiation was 100% (P =.03).
  • EFS in 26 patients with histology-directed treatment (LSA2-L2 or ADCOMP for lymphoblastic, other therapy for nonlymphoblastic) was 92.2% +/- 5.3%, and in five patients with nonhistology-directed treatment it was 40.0% +/- 21.9% (P <.001).
  • CONCLUSION: NHL arising in bone is a heterogeneous type of NHL that makes up approximately 2.0% of NHL in children and adolescents on CCG studies.
  • Response and survival in this young age group seem superb, with histology-directed treatment protocols without radiation in both localized and disseminated disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Neoplasms / drug therapy. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Male. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11981000.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  •  go-up   go-down


5. Petersdorf SH, Wood DE: Lymphoproliferative disorders presenting as mediastinal neoplasms. Semin Thorac Cardiovasc Surg; 2000 Oct;12(4):290-300
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both Hodgkin's disease and non-Hodgkin's lymphoma may present in the mediastinum.
  • The most common types of non-Hodgkin's lymphoma involving the mediastinum include lymphoblastic lymphoma and mediastinal large cell lymphoma.
  • Symptoms associated with a mediastinal presentation of a lymphoproliferative disorder are often attributable to compression of mediastinal structures (eg, superior vena cava syndrome) or invasion of thoracic structures such as the pericardium or pleura.
  • Although staging can be performed with routine imaging studies, surgical intervention is often required to ensure accurate histologic diagnosis of these lymphomas.
  • Once a diagnosis has been established, therapeutic modalities usually include chemotherapy and/or radiotherapy.
  • [MeSH-major] Lymphoma. Mediastinal Neoplasms

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 by W.B. Saunders Company
  • (PMID = 11154724.001).
  • [ISSN] 1043-0679
  • [Journal-full-title] Seminars in thoracic and cardiovascular surgery
  • [ISO-abbreviation] Semin. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] UNITED STATES
  • [Number-of-references] 41
  •  go-up   go-down


6. Tang YJ, Tang JY, Pan C, Xue HL, Chen J, Shen SH, Dong L, Zhou M, Wang YP, Gu LJ, Jiang H, Ye QD: [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children]. Zhonghua Er Ke Za Zhi; 2009 Sep;47(9):687-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and treatment outcome of 36 cases with non-Hodgkin's lymphoma arising from mediastinum in children].
  • OBJECTIVE: Non-Hodgkin's lymphoma (NHL) presenting as mediastinal mass is usually progressive and may cause severe respiratory distress and death.
  • This study aimed to summarize the clinical features and prognosis of NHL arising from mediastinum.
  • Their clinical characteristics, pathologic classification, diagnosis, outcome of different treatment protocol were retrospectively analyzed.
  • Diagnosis was established on pathology that was achieved by mediastinal mass or peripheral lymph nodes biopsy, while some were diagnosed based on bone marrow or pleural effusion cytology study and immunophenotyping.
  • Patients who experienced superior vena cava syndrome (SVCS) and/or superior mediastinum syndrome (SMS) received induction chemotherapy with cyclophosphamide (C), vincristine (O) and prednisone (P) for one week.
  • Of them, 24 were lymphoblastic lymphoma and 3 were anaplastic large cell lymphoma.
  • All the 36 cases were T-cell type.
  • Twenty-four patients had urgent situation of SVCS and airway obstruction, 22 patients reached good response after emergency management including COP induction chemotherapy and pleural effusion suction.
  • Thirteen patients died from disease progression, relapse or severe infection during chemotherapy.
  • CONCLUSION: Establishment of a diagnosis as soon as possible was important to reduce the mortality and improve long term survival of patients.
  • Induction chemotherapy for emergency situation was efficacious.
  • [MeSH-major] Lymphoma, Non-Hodgkin. Mediastinal Neoplasms

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20021793.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


7. Cohen H, Bielorai B, Harats D, Toren A, Pinhas-Hamiel O: Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia. Pediatr Blood Cancer; 2010 May;54(5):703-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
  • OBJECTIVE: To determine the incidence and clinical consequences of asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia (ALL).
  • METHODS: Sixty-five newly diagnosed children and adolescents aged 0.4-21 years with ALL or lymphoblastic lymphoma were retrospectively evaluated for lipid abnormalities.
  • RESULTS: Prior to treatment, mean cholesterol level was 149 +/- 50 mg/dl, and increased to maximal level 274 +/- 124 mg/dl during treatment.
  • Mean TG level during treatment was 459 +/- 526 mg/dl (range 54-3,009).
  • One of the 12 patients with TG >400 mg/dl developed left saggital sinus thrombosis and left frontal lobe infarct.
  • TG level at the time of the event was 2,640 mg/dl.
  • None of the five patients with TG levels >1,000 mg/dl developed pancreatitis.
  • Lipid abnormalities normalized in all children upon completion of asparaginase treatment.
  • CONCLUSIONS: Abnormalities of lipid profile in children with ALL during asparaginase therapy are relatively common.
  • We recommend measuring TG before and during asparaginase treatment.
  • Initiation of conservative treatment could prevent further increase of TG and decrease the risk of potential complications.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Asparaginase / adverse effects. Drug Monitoring. Hypercholesterolemia / prevention & control. Hypertriglyceridemia / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Clofibric Acid / administration & dosage. Diet, Carbohydrate-Restricted. Diet, Fat-Restricted. Fasting. Female. Humans. Hypolipidemic Agents / administration & dosage. Infant. Israel / epidemiology. Male. Remission Induction. Retrospective Studies. Young Adult

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • MedlinePlus Health Information. consumer health - Cholesterol.
  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20063421.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Hypolipidemic Agents; 53PF01Q249 / Clofibric Acid; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


8. Kfoury-Baz EM, Nassar RA, Tanios RF, Otrock ZK, Youssef AM, Albany C, Bazarbachi A, Salem ZM: Plasmapheresis in asparaginase-induced hypertriglyceridemia. Transfusion; 2008 Jun;48(6):1227-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Asparaginase is an essential component of the chemotherapy regimens during the induction and intensification phases for acute lymphoblastic leukemia and lymphoblastic lymphoma.
  • CASE REPORT: This study reports the case of an adult patient presenting with acute pancreatitis secondary to severe hypertriglyceridemia after asparaginase treatment during the consolidation phase of lymphoblastic lymphoma.
  • CONCLUSIONS: Our case demonstrates that plasmapheresis in severe cases of hypertriglyceridemia offers a safe and efficient treatment option for symptomatic patients.

  • MedlinePlus Health Information. consumer health - Triglycerides.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Transfusion. 2009 Jan;49(1):185; author reply 185-6 [19140812.001]
  • (PMID = 18410253.001).
  • [ISSN] 0041-1132
  • [Journal-full-title] Transfusion
  • [ISO-abbreviation] Transfusion
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Triglycerides; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


9. Zheng C, Liu X, Wu J, Cai X, Zhu W, Sun Z: Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia? Am J Hematol; 2010 Oct;85(10):817-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Which steroids should we choose for the treatment of adult acute lymphoblastic leukemia?
  • Corticosteroids are essential and one of the mainstays in the treatment of acute lymphoblastic leukemia (ALL).
  • In vitro assays show that dexamethasone(DXM) is five to six times more cytotoxic to leukemic lymphoblasts than prednisolone (PDN) [1], and the use of DXM as an alternative drug for PDN is an important issue in the treatment of childhood ALL.
  • Recently, Labar et al. [2] reported their first investigation in comparison of the antileukemic activity and toxicity between DXM and PDN for adult patients with ALL and lymphoblastic lymphoma (LBL) through a randomized clinical trial (the ALL-4 trial of the EORTC Leukemia Group), and the author concluded that DXM as a steroid therapy for adult patients with ALL/LBL did not show any benefit compared with PDN, which did not support the experience from several other pediatric studies.
  • In our study, we also evaluate the role of DXM compared with PDN during induction or subsequent phases of therapy in adult ALL with emphasis on SR group.
  • [MeSH-major] Dexamethasone. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisolone
  • [MeSH-minor] Adult. Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infection / epidemiology. Male. Middle Aged. Remission Induction. Risk. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20815080.001).
  • [ISSN] 1096-8652
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Publication-type] Letter; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone; EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


10. Kang W, Hahn JS, Kim JS, Cheong JW, Yang WI: Nine-year survival of lymphoblastic lymphoma patients. Yonsei Med J; 2006 Aug 31;47(4):466-74
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nine-year survival of lymphoblastic lymphoma patients.
  • This study aimed to analyze the overall survival period of adult lymphoblastic lymphoma patients treated with various therapeutic regimens, and to assess the determinants affecting survival outcome.
  • Twenty-five adult patients with lymphoblastic lymphoma who had been treated at Severance Hospital, Yonsei University College of Medicine, Seoul, Korea from June 1996 to June 2005 were analyzed retrospectively.
  • As an initial remission induction chemotherapy, the hyper-CVAD regimen was performed in eight patients, the Stanford/Northern California Oncology Group (NCOG) regimen in five, the CAVOP regimen in four, the m-BACOP regimen in three, and the CHOP regimen in one patient.
  • Patients were divided into two groups according to their therapeutic modalities.
  • Twenty patients received conventional chemotherapy alone and five received subsequent PBSCT after conventional chemotherapy.
  • The OS rate in patients treated with conventional chemotherapy alone was 19.8%, whereas patients treated with subsequent PBSCT after chemotherapy showed 50% overall survival (p=0.25).
  • The Stanford/NCOG regimen is an effective initial choice of therapy for lymphoblastic lymphoma patients, and is superior to the hyper-CVAD regimen in complete response rate and overall survival rate (p =0.36).
  • Addition of PBSCT after chemotherapy may be needed for achieving optimal outcomes.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Agents / pharmacology. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prognosis. Retrospective Studies. Stem Cell Transplantation / methods. Time Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood Rev. 2000 Mar;14(1):1-13 [10805257.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] Ann Hematol. 2001 Nov;80(11):647-52 [11757723.001]
  • [Cites] Cytotherapy. 2002;4(3):223-40 [12194719.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] Yonsei Med J. 1997 Oct;38(5):270-84 [9409190.001]
  • [Cites] Yonsei Med J. 2003 Oct 30;44(5):757-70 [14584090.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Cancer Res. 1971 Nov;31(11):1860-1 [5121694.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Semin Oncol. 1990 Feb;17(1):96-103 [2406921.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • (PMID = 16941734.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Other-IDs] NLM/ PMC2687725
  •  go-up   go-down


11. Lin P, Jones D, Dorfman DM, Medeiros LJ: Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement. Am J Surg Pathol; 2000 Nov;24(11):1480-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Precursor B-cell lymphoblastic lymphoma: a predominantly extranodal tumor with low propensity for leukemic involvement.
  • Precursor B-cell lymphoblastic lymphoma (B-LBL) is uncommon and accounts for less than 10% of cases of lymphoblastic lymphoma.
  • We collected 25 cases of B-LBL, occurring in children and adults, and report the clinical and histologic features.
  • Patients with concurrent precursor B-cell acute lymphoblastic leukemia (B-ALL) or a history thereof were excluded.
  • There was no evidence of bone marrow disease at the time of diagnosis in 23 patients; two patients had focal (<5%) involvement.
  • The treatment and survival data available for a subset of patients with B-LBL were compared with those from a series of patients with B-ALL at our institution.
  • The primary sites of disease were skin (nine cases), bones (five cases), soft tissue (four cases), lymph nodes, (three cases), breast (two cases), stomach and colon (one case), and mediastinum (one case).
  • Clinical stage was stage I in 13 cases, stage II in seven cases, stage III in three cases, and stage IV in two cases.
  • Histologically, each neoplasm was diffuse and composed of small to medium-sized lymphoid cells with blastic nuclear chromatin and a high mitotic rate.
  • All cases were positive for B-cell antigens and terminal deoxynucleotidyl transferase.
  • Of 14 patients with available survival data, all achieved complete clinical response after combination chemotherapy (13 patients) or surgical excision followed by local irradiation (one patient).
  • Five (35.7%) patients subsequently relapsed, including the patient who had received only irradiation, and four of these patients died after a median survival time of 60 months.
  • None of the patients had leukemia, although one patient developed extensive bone marrow involvement.
  • Unlike precursor T-cell lymphoblastic lymphoma, which commonly involves lymph nodes and the mediastinum, B-LBL usually involves extranodal sites, most often the skin, and rarely presents as a mediastinal mass.
  • With aggressive chemotherapy, patients with precursor B-LBL rarely develop leukemia and appear to have a better prognosis than do patients with B-ALL.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Precancerous Conditions / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11075849.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / DNA, Neoplasm
  •  go-up   go-down


12. Ogilvie GK, Fettman MJ, Mallinckrodt CH, Walton JA, Hansen RA, Davenport DJ, Gross KL, Richardson KL, Rogers Q, Hand MS: Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study. Cancer; 2000 Apr 15;88(8):1916-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of fish oil, arginine, and doxorubicin chemotherapy on remission and survival time for dogs with lymphoma: a double-blind, randomized placebo-controlled study.
  • This double-blind, randomized study was designed to evaluate the hypothesis that polyunsaturated n-3 fatty acids can improve metabolic parameters, decrease chemical indices of inflammation, enhance quality of life, and extend disease free interval and survival time for dogs treated for lymphoblastic lymphoma with doxorubicin chemotherapy.
  • METHODS: Thirty-two dogs with lymphoma were randomized to receive one of two diets supplemented with menhaden fish oil and arginine (experimental diet) or an otherwise identical diet supplemented with soybean oil (control diet).
  • Parameters examined included blood concentrations of glucose, lactic acid, and insulin in response to glucose and diet tolerance tests; alpha-1 acid glycoprotein; tumor necrosis factor; interleukin-6; body weight; amino acid profiles; resting energy expenditure; disease free interval (DFI); survival time (ST); and clinical performance scores.
  • Increasing C22:6 levels were significantly (P < 0.05) associated with longer DFI and ST for dogs with Stage III lymphoma fed the experimental diet.
  • CONCLUSIONS: Fatty acids of the n-3 series normalize elevated blood lactic acid in a dose-dependent manner, resulting in an increase in DFI and ST for dogs with lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arginine / therapeutic use. Cachexia / prevention & control. Doxorubicin / therapeutic use. Fatty Acids / pharmacology. Fish Oils / pharmacology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / veterinary
  • [MeSH-minor] Animals. Diet. Dietary Supplements. Disease Models, Animal. Disease-Free Survival. Docosahexaenoic Acids / administration & dosage. Dogs. Dose-Response Relationship, Drug. Double-Blind Method. Eicosapentaenoic Acid / administration & dosage. Lactic Acid / blood. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. LACTIC ACID .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 American Cancer Society.
  • (PMID = 10760770.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 2 CA 29582
  • [Publication-type] Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Fatty Acids; 0 / Fish Oils; 25167-62-8 / Docosahexaenoic Acids; 33X04XA5AT / Lactic Acid; 80168379AG / Doxorubicin; 94ZLA3W45F / Arginine; AAN7QOV9EA / Eicosapentaenoic Acid
  •  go-up   go-down


13. Tangen JM, Fløisand Y, Haukås E, Naess IA, Skjelbakken T, Stapnes C, Tjønnfjord GE: [Survival in adults with acute lymphoblastic leukaemia]. Tidsskr Nor Laegeforen; 2010 Sep 9;130(17):1710-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Survival in adults with acute lymphoblastic leukaemia].
  • BACKGROUND: The Norwegian treatment protocol for acute lymphoblastic leukaemia in adults was introduced in 1982 and has undergone minor changes thereafter.
  • This article presents survival data for Norwegian adults with acute lymphoblastic leukaemia on a national basis.
  • MATERIAL AND METHODS: Data for all patients between 15 and 65 years, who were diagnosed with acute lymphoblastic leukaemia in the period 2000-2007 according to The Norwegian Registry for Acute Leukaemia and Lymphoblastic Lymphoma, and were treated with chemotherapy with a curative intent were analysed for survival.
  • RESULTS: 128 patients were diagnosed with acute lymphoblastic leukaemia in the study period.
  • One explanation can be that the Norwegian treatment program is more intensive than most treatment protocols used in other countries.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality
  • [MeSH-minor] Adolescent. Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Middle Aged. Norway / epidemiology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / mortality. Prognosis. Registries. Survival Rate. Young Adult

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20835280.001).
  • [ISSN] 0807-7096
  • [Journal-full-title] Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række
  • [ISO-abbreviation] Tidsskr. Nor. Laegeforen.
  • [Language] nor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Norway
  •  go-up   go-down


14. Fresneau B, Oberlin O, Brugières L, Valteau-Couanet D, Patte C: [Malignant primary cardiac tumors in childhood and adolescence]. Arch Pediatr; 2010 May;17(5):495-501
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant primary cardiac tumors in childhood and adolescence].
  • [Transliterated title] Les tumeurs cardiaques primitives malignes de l'enfant et de l'adolescent.
  • The majority of them are benign, with only 10% malignant.
  • Among malignant cardiac tumors, sarcoma (rhabdomyosarcoma, angiosarcoma, synovial sarcoma) and lymphoma (Burkitt's lymphoma, large B-cell lymphoma, lymphoblastic lymphoma) predominate.
  • There are few published pediatric series on malignant primary cardiac tumors.
  • We report here 3 observations of primary malignant cardiac tumors, 2 cases of sarcoma (angiosarcoma and synovial sarcoma) and 1 case of Burkitt's lymphoma.
  • A precise pathological diagnosis is necessary for the proper management of these patients.
  • For sarcoma, treatment associates surgery and chemotherapy.
  • Surgery should be as complete as possible because of the lack of chemotherapy sensitivity of some sarcomas, mainly angiosarcoma and synovial sarcoma.
  • For primary cardiac lymphoma, management should not be different from lymphoma in other locations.
  • Chemotherapy is the main treatment, and surgery has to be used only when complications occur.
  • Prognosis depends on histology and not lymphoma location, and so is better than the prognosis for sarcoma.
  • [MeSH-major] Burkitt Lymphoma / diagnosis. Heart Neoplasms / diagnosis. Hemangiosarcoma / diagnosis. Sarcoma, Synovial / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Cough / etiology. Diagnosis, Differential. Dyspnea / etiology. Echocardiography. Fatal Outcome. Female. Heart Atria / pathology. Heart Atria / surgery. Humans. Male. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Neoplasm, Residual / diagnosis. Neoplasm, Residual / pathology. Pulmonary Heart Disease / diagnosis. Pulmonary Heart Disease / etiology. Superior Vena Cava Syndrome / diagnosis. Superior Vena Cava Syndrome / etiology. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20338733.001).
  • [ISSN] 1769-664X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


15. Teh HS, Fadilah SA, Leong CF: Transverse myelopathy following intrathecal administration of chemotherapy. Singapore Med J; 2007 Feb;48(2):e46-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transverse myelopathy following intrathecal administration of chemotherapy.
  • Transverse myelopathy is one of the rare complications following administration of intrathecal chemotherapy.
  • One patient was a 17-year-old Malay man who had lymphoblastic lymphoma in the leukaemic phase, while the other patient was a 40-year-old Malay man with relapsed Hodgkin's lymphoma.
  • Both cases demonstrated variability in onset of symptoms, clinical progression and final outcome from the complication.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Cytarabine / adverse effects. Methotrexate / adverse effects. Myelitis, Transverse / chemically induced
  • [MeSH-minor] Adolescent. Adult. Fatal Outcome. Hodgkin Disease / drug therapy. Humans. Injections, Spinal. Leukemic Infiltration / drug therapy. Male. Peripheral Blood Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17304378.001).
  • [ISSN] 0037-5675
  • [Journal-full-title] Singapore medical journal
  • [ISO-abbreviation] Singapore Med J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Singapore
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


16. Dabaja BS, Ha CS, Thomas DA, Wilder RB, Gopal R, Cortes J, Bueso-Ramos C, Hess MA, Cox JD, Kantarjian HM: The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma. Cancer; 2002 May 15;94(10):2738-44
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of local radiation therapy for mediastinal disease in adults with T-cell lymphoblastic lymphoma.
  • BACKGROUND: Mediastinal recurrence remains the most common cause of failure in patients with mediastinal T-cell lymphoblastic lymphoma (LBL).
  • The role of mediastinal radiation therapy in improving local disease control and overall prognosis is not well-known with modern intensive chemotherapy.
  • The objective of this study was to investigate the role of mediastinal radiation therapy in patients who achieve a complete response (CR) to chemotherapy.
  • METHODS: The authors reviewed 47 patients with mediastinal T-cell LBL with or without bone marrow (BM) involvement who presented between 1980 and 1998.
  • The initial chemotherapy regimens were fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) in 23 patients; cyclophosphamide, vincristine, doxorubicin, and dexamethasone in 9 patients; vincristine, doxorubicin, and dexamethasone in 4 patients; cyclophosphamide, doxorubicin, vincristine, and prednisone in 4 patients; and other in 7 patients.
  • Forty-three patients achieved a CR to chemotherapy and were the subject of this analysis.
  • Nineteen of those patients received adjuvant mediastinal radiation therapy at a dose ranging from 26 grays (Gy) to 39 Gy.
  • RESULTS: There was no difference in patient characteristics between the 19 patients who were treated with mediastinal radiation therapy and the 24 patients who did not receive mediastinal radiation therapy.
  • None of 19 patients who received radiation therapy experienced a mediastinal recurrence compared with 8 of 24 patients who did not receive radiation therapy and experienced a mediastinal recurrence.
  • Patients who were treated with mediastinal radiation therapy had a significantly better mediastinal FFP rate (P = 0.01), but the differences in overall FFP and OS rates were not significant (P = 0.14 and P = 0.25, respectively).
  • The effectiveness of the hyper-CVAD regimen seemed to underscore the role of mediastinal radiation therapy; only 2 patients experienced a recurrence among 16 patients who received mediastinal radiation therapy, both outside the mediastinum.
  • This compared with two patients who experienced a recurrence among six patients who did not receive mediastinal radiation therapy, both in the mediastinum.
  • CONCLUSIONS: Local radiation therapy significantly decreased the risk of mediastinal recurrence in adult patients with mediastinal T-cell lymphoblastic lymphoma.
  • The benefit of adjuvant radiation therapy was particularly evident in patients treated with more intensive chemotherapy regimens.
  • [MeSH-major] Mediastinal Neoplasms / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Female. Hepatomegaly / complications. Humans. Lymph Nodes / pathology. Male. Pleural Effusion, Malignant / complications. Prednisone / therapeutic use. Splenomegaly / complications. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12173345.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol; CVAD protocol
  •  go-up   go-down


17. Micallef IN, Apostolidis J, Rohatiner AZ, Wiggins C, Crawley CR, Foran JM, Leonhardt M, Bradburn M, Okukenu E, Salam A, Matthews J, Cavenagh JD, Gupta RK, Lister TA: Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma. Hematol J; 2000;1(6):367-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Factors which predict unsuccessful mobilisation of peripheral blood progenitor cells following G-CSF alone in patients with non-Hodgkin's lymphoma.
  • INTRODUCTION: High-dose therapy with haematopoietic progenitor cell support has increasingly been utilised for patients with haematological malignancies.
  • Peripheral blood is the stem cell source of choice, however, various mobilisation strategies are used by different centres.
  • PATIENTS AND METHODS: Over a 2-year period, 52 patients with non-Hodgkin's lymphoma (median age 47 years, range 16-64 years) underwent peripheral blood progenitor cell mobilisation using G-CSF alone (16 microg/kg/day).
  • The histological subtypes of non-Hodgkin's lymphoma comprised: follicular (24 patients), diffuse large B-cell (14 patients), lymphoplasmacytoid (four patients), mantle cell (three patients), lymphoblastic lymphoma (one patient) and small lymphocytic lymphoma/chronic lymphocytic leukaemia (six patients).
  • The median interval from diagnosis of non-Hodgkin's lymphoma to mobilisation was 27 months (range 2 months to 17 years).
  • The median number of prior treatment episodes was 2 (range 1-5); 26 patients had received fludarabine alone or in combination.
  • At the time of peripheral blood progenitor cell mobilisation, 20 patients were in 1st remission and 32 were in > or =2nd remission; 30 patients were in partial remission and 22 were in complete remission; the bone marrow was involved in nine patients.
  • RESULTS: Peripheral blood progenitor cell mobilisation/harvest was unsuccessful in 19 out of 52 (37%) patients (mobilisation: 18, harvest: 1).
  • The factors associated with unsuccessful mobilisation or harvest were: prior fludarabine therapy (P=0.002), bone marrow involvement at diagnosis (P=0.002), bone marrow involvement anytime prior to mobilisation (P=0.02), histological diagnosis of follicular, mantle cell, or lymphoplasmacytoid lymphoma, or small lymphocytic lymphoma/chronic lymphocytic leukaemia (P=0.03) and female gender (P=0.04).
  • CONCLUSION: Although peripheral blood progenitor cells can be successfully mobilised and harvested from the majority of patients with non-Hodgkin's lymphoma after treatment with G-CSF alone, the latter is unsuccessful in approximately one-third of patients.
  • These factors should be taken into account when patients are being considered for high-dose treatment.

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. FLUDARABINE .
  • Hazardous Substances Data Bank. VIDARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11920216.001).
  • [ISSN] 1466-4860
  • [Journal-full-title] The hematology journal : the official journal of the European Haematology Association
  • [ISO-abbreviation] Hematol. J.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 143011-72-7 / Granulocyte Colony-Stimulating Factor; FA2DM6879K / Vidarabine; P2K93U8740 / fludarabine
  •  go-up   go-down


18. Vakiani E, Savage DG, Pile-Spellman E, El-Tamer M, Singh IR, Murty VS, Alobeid B, Bhagat G: T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature. Am J Hematol; 2005 Nov;80(3):216-22
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-Cell lymphoblastic lymphoma presenting as bilateral multinodular breast masses: a case report and review of the literature.
  • Non-Hodgkin lymphoma of T-cell lineage involving the breast is rare.
  • We report on a 41-year-old woman with T-cell lymphoblastic lymphoma who presented with multiple bilateral breast masses.
  • The patient was treated with intensive chemotherapy and mediastinal and whole-brain irradiation.
  • She remains in complete remission 24 months after diagnosis.
  • The clinical, histologic, phenotypic, and cytogenetic features are described, with a review of the literature.
  • [MeSH-major] Breast Neoplasms / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adult. Cranial Irradiation. Diagnosis, Differential. Female. Humans. Radiotherapy, Adjuvant. Remission Induction / methods

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16247747.001).
  • [ISSN] 0361-8609
  • [Journal-full-title] American journal of hematology
  • [ISO-abbreviation] Am. J. Hematol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / R01 CA149719
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


19. Sakurai N, Tateoka K, Taguchi J, Terada T: Primary precursor B-cell lymphoblastic lymphoma of the ovary: case report and review of the literature. Int J Gynecol Pathol; 2008 Jul;27(3):412-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary precursor B-cell lymphoblastic lymphoma of the ovary: case report and review of the literature.
  • Primary ovarian lymphoma is a rare disease, and its definition is still controversial.
  • Many cases of primary ovarian lymphoma are diagnosed as diffuse large B-cell type, whereas the precursor lymphoblastic type is extremely rare.
  • Herein, we describe a case of precursor B-cell lymphoblastic lymphoma of the ovary that was successfully treated with surgery and chemotherapy.
  • Exploratory laparotomy and right salpingo-oophorectomy were performed, and the diagnosis of precursor B-cell lymphoblastic lymphoma was established.
  • The patient was treated with a combination of chemotherapy and is currently disease-free 1 year after surgery.
  • To our best knowledge, this is the fourth reported case of precursor lymphoblastic lymphoma of the ovary.
  • [MeSH-major] Ovarian Neoplasms / pathology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18580320.001).
  • [ISSN] 1538-7151
  • [Journal-full-title] International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists
  • [ISO-abbreviation] Int. J. Gynecol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


21. Sweetenham JW: Lymphoblastic lymphoma in adults. Curr Hematol Malig Rep; 2006 Dec;1(4):241-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma in adults.
  • Understanding of the pathogenesis and biology of precursor T-cell and B-cell neoplasms has advanced significantly with the description of gene expression profiling studies, especially in T-cell disease.
  • Optimal treatment strategies for adult lymphoblastic lymphoma are uncertain, although current evidence supports the use of regimens similar to those used in acute lymphoblastic leukemia, with intensive induction therapy, central nervous system prophylaxis, and prolonged consolidation maintenance therapy.
  • Current studies do not demonstrate a benefit from stem cell transplantation in first remission, although this approach is probably beneficial in relapsed disease.
  • Identification of new therapeutic targets by further molecular studies is required.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. B-Lymphocytes / pathology. Child. Combined Modality Therapy. Gene Expression Regulation, Neoplastic. Gene Rearrangement. Hematopoietic Stem Cell Transplantation. Humans. Mediastinal Neoplasms / drug therapy. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Multicenter Studies as Topic / statistics & numerical data. Prognosis. Randomized Controlled Trials as Topic / statistics & numerical data. Remission Induction. Salvage Therapy. T-Lymphocytes / pathology. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1993 Sep 30;329(14 ):987-94 [8141877.001]
  • [Cites] Leuk Lymphoma. 1994 Oct;15(3-4):291-6 [7866277.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2927-36 [11387366.001]
  • [Cites] J Nucl Med. 2002 Aug;43(8):1018-27 [12163626.001]
  • [Cites] Am J Clin Pathol. 2004 Feb;121(2):268-74 [14983942.001]
  • [Cites] Ann Intern Med. 1978 Sep;89(3):319-24 [686542.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):101-8 [10613454.001]
  • [Cites] Cancer Cell. 2002 Feb;1(1):75-87 [12086890.001]
  • [Cites] Br J Haematol. 1989 Sep;73(1):82-7 [2803982.001]
  • [Cites] Blood. 2002 Jun 15;99(12):4379-85 [12036865.001]
  • [Cites] Blood. 1999 Jun 1;93(11):3931-9 [10339502.001]
  • [Cites] Cancer. 1987 Jul 15;60(2):183-90 [2954631.001]
  • [Cites] Blood. 2003 Jul 1;102(1):262-8 [12637319.001]
  • [Cites] Cancer. 1981 Dec 1;48(11):2347-57 [6895347.001]
  • [Cites] Ann Oncol. 1995 May;6(5):445-51 [7545428.001]
  • [Cites] J Clin Oncol. 1994 Jul;12(7):1358-65 [8021726.001]
  • [Cites] J Clin Oncol. 1986 Jan;4(1):57-67 [3510283.001]
  • [Cites] Blood. 2004 Jan 15;103(2):442-50 [14504110.001]
  • [Cites] J Clin Invest. 1985 Jul;76(1):248-53 [2410458.001]
  • [Cites] J Clin Oncol. 1986 Nov;4(11):1628-37 [3772416.001]
  • [Cites] Ann Oncol. 1990;1(2):141-6 [2078494.001]
  • [Cites] Mol Diagn. 1996 Jun;1(2):139-151 [10330209.001]
  • [Cites] Leukemia. 2005 Jun;19(6):945-52 [15800666.001]
  • [Cites] J Pathol. 1999 Jul;188(3):267-70 [10419594.001]
  • [Cites] Blood. 2003 Apr 1;101(7):2476-82 [12456505.001]
  • [Cites] J Clin Oncol. 1992 Apr;10(4):644-6 [1548528.001]
  • [Cites] Blood. 1997 Jun 1;89(11):3909-18 [9166827.001]
  • [Cites] Blood. 2004 Sep 15;104(6):1624-30 [15178574.001]
  • [Cites] Bone Marrow Transplant. 2003 Apr;31(8):667-78 [12692607.001]
  • [Cites] Blood. 2005 Aug 15;106(4):1376-81 [15860666.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):619-25 [9681075.001]
  • [Cites] Leukemia. 2003 Nov;17(11):2220-4 [14576732.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] Bone Marrow Transplant. 1992 Jul;10(1):33-8 [1515876.001]
  • [Cites] Cancer. 2002 May 15;94(10):2738-44 [12173345.001]
  • [Cites] Mod Pathol. 2004 Apr;17(4):423-9 [14976526.001]
  • [Cites] Leuk Lymphoma. 1996 Nov;23(5-6):577-82 [9031089.001]
  • [Cites] Cancer. 1979 Dec;44(6):1990-9 [389403.001]
  • [Cites] Blood. 1981 Apr;57(4):679-84 [6970598.001]
  • (PMID = 20425319.001).
  • [ISSN] 1558-822X
  • [Journal-full-title] Current hematologic malignancy reports
  • [ISO-abbreviation] Curr Hematol Malig Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 42
  •  go-up   go-down


22. Cavalcante AS, Anbinder AL, Pontes EM, Carvalho YR: B-cell lymphoblastic lymphoma in the maxilla of a child: a rare case report. Int J Oral Maxillofac Surg; 2009 Dec;38(12):1326-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] B-cell lymphoblastic lymphoma in the maxilla of a child: a rare case report.
  • Lymphoblastic lymphoma is a malignant neoplasia that originates from B or T lymphocyte precursors and rarely occurs in the mouth.
  • The authors report a rare case of B-cell lymphoblastic lymphoma in the maxilla of a child.
  • Clinical examination revealed facial asymmetry with a swelling of the right maxilla, covered by healthy mucosa and painful to palpation.
  • Based on the hypothesis of malignant neoplasia of hematopoietic origin, an incisional biopsy was performed.
  • Histological examination revealed malignant neoplasia with proliferation of monomorphic, lymphoid cells.
  • After the diagnosis of B-cell lymphoblastic lymphoma, the patient underwent chemotherapy, but died of leukoencephalopathy and demyelinization caused by high doses of methotrexate.
  • [MeSH-major] Lymphoma, B-Cell / diagnosis. Maxillary Neoplasms / diagnosis. Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Antigens, CD20 / analysis. Antigens, CD45 / analysis. Antigens, CD79 / analysis. Biomarkers, Tumor / analysis. Biopsy. Child. DNA Nucleotidylexotransferase / analysis. Facial Asymmetry / diagnosis. Fatal Outcome. Female. Humans. Immunohistochemistry. Neprilysin / analysis. Radiography, Panoramic. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Int J Oral Maxillofac Surg. 2010 Feb;39(2):196
  • (PMID = 19665353.001).
  • [ISSN] 1399-0020
  • [Journal-full-title] International journal of oral and maxillofacial surgery
  • [ISO-abbreviation] Int J Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Antigens, CD20; 0 / Antigens, CD79; 0 / Biomarkers, Tumor; EC 2.7.7.31 / DNA Nucleotidylexotransferase; EC 3.1.3.48 / Antigens, CD45; EC 3.4.24.11 / Neprilysin
  •  go-up   go-down


23. Labar B, Suciu S, Willemze R, Muus P, Marie JP, Fillet G, Berneman Z, Jaksic B, Feremans W, Bron D, Sinnige H, Mistrik M, Vreugdenhil G, De Bock R, Nemet D, Gilotay C, Amadori S, de Witte T, EORTC Leukemia Group: Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group. Haematologica; 2010 Sep;95(9):1489-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dexamethasone compared to prednisolone for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma: final results of the ALL-4 randomized, phase III trial of the EORTC Leukemia Group.
  • BACKGROUND: Corticosteroids are a standard component of the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
  • DESIGN AND METHODS: Adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma were randomized to receive, as part of their induction therapy on days 1-8 and 15-22, either dexamethasone 8 mg/m(2) or prednisolone 60 mg/m(2).
  • Those who reached complete remission were given two courses of consolidation therapy with high-dose cytarabine and mitoxantrone and methotrexate and asparaginase.
  • Subsequently patients younger than 50 years, with a suitable donor, were to undergo allogeneic stem cell transplantation, whereas the others were planned to receive either an autologous stem cell transplant or high-dose maintenance chemotherapy with prophylactic central nervous system irradiation.
  • Randomization was done with a minimization technique.
  • After induction and the course of first consolidation therapy, 131 (80.4%) patients in the dexamethasone group and 124 (76.5%) in the prednisolone group achieved complete remission.
  • No significant difference was observed between the two treatment groups with regards to 6-year event-free survival rates (+/-SE) which were 25.9% (3.6%) and 28.7% (3.5%) in the dexamethasone and prednisolone groups, respectively (P=0.82, hazard ratio 0.97; 95% confidence interval, 0.75-1.25).
  • CONCLUSIONS: In the ALL-4 trial in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma, treatment with dexamethasone did not show any advantage over treatment with prednisolone.

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. PREDNISOLONE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] N Engl J Med. 1986 Mar 20;314(12):729-35 [3513012.001]
  • [Cites] J Clin Endocrinol Metab. 1975 Jun;40(6):1073-7 [1133157.001]
  • [Cites] Med Pediatr Oncol. 1991;19(4):269-75 [2056971.001]
  • [Cites] Bone Marrow Transplant. 1994 Nov;14(5):767-74 [7889010.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Feb;17(1):1-12 [7743230.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):911-8 [8622039.001]
  • [Cites] Med Pediatr Oncol. 1996 Aug;27(2):114-21 [8649318.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2370-6 [8708730.001]
  • [Cites] Cancer. 2004 Dec 15;101(12):2788-801 [15481055.001]
  • [Cites] Br J Haematol. 2005 Jun;129(6):734-45 [15952999.001]
  • [Cites] Blood. 2005 Dec 1;106(12):3760-7 [16105981.001]
  • [Cites] N Engl J Med. 2006 Jan 12;354(2):166-78 [16407512.001]
  • [Cites] Leukemia. 2007 Apr;21(4):593-4 [17301807.001]
  • [Cites] Semin Hematol. 2007 Oct;44(4):267-73 [17961726.001]
  • [Cites] Health Qual Life Outcomes. 2008;6:103 [19036151.001]
  • [Cites] Pediatr Blood Cancer. 2009 Dec;53(6):984-91 [19621425.001]
  • [Cites] J Clin Oncol. 1996 Jan;14(1):18-24 [8558195.001]
  • [Cites] Leukemia. 2000 Mar;14(3):356-63 [10720126.001]
  • [Cites] Cancer. 2000 Apr 15;88(8):1964-9 [10760775.001]
  • [Cites] Hematol Oncol Clin North Am. 2000 Dec;14(6):1307-25, ix [11147225.001]
  • [Cites] Leukemia. 2000 Dec;14(12):2193-4 [11187910.001]
  • [Cites] Blood. 2001 Mar 1;97(5):1211-8 [11222362.001]
  • [Cites] Pediatr Hematol Oncol. 2001 Apr-May;18(3):187-91 [11293286.001]
  • [Cites] Rev Clin Exp Hematol. 2002 Jun;6(2):114-41; discussion 200-2 [12196212.001]
  • [Cites] Blood. 2003 May 15;101(10):3809-17 [12531809.001]
  • [Cites] Cancer. 2003 Jun 1;97(11):2898-903 [12767105.001]
  • [Cites] Haematologica. 2004 Jul;89(7):809-17 [15257932.001]
  • [Cites] J Clin Oncol. 1987 Feb;5(2):202-7 [3806166.001]
  • (PMID = 20378563.001).
  • [ISSN] 1592-8721
  • [Journal-full-title] Haematologica
  • [ISO-abbreviation] Haematologica
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA011488; United States / NCI NIH HHS / CA / CA11488-25; United States / NCI NIH HHS / CA / CA11489-39
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 7S5I7G3JQL / Dexamethasone; 9PHQ9Y1OLM / Prednisolone
  • [Other-IDs] NLM/ PMC2930949
  •  go-up   go-down


24. Iino M: [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma]. Rinsho Ketsueki; 2009 Jan;50(1):49-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Severe liver injury following nelarabine chemotherapy for T-cell lymphoblastic lymphoma].
  • A 41-year-old man received allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic lymphoma.
  • Combination chemotherapy (etoposide, prednisolone, daunorubicin, vincristine) was performed, but the effect was limited, necessitating nelarabine administration.
  • DDW-J 2004 guidelines on drug-induced liver injury indicated nelarabine as the most plausible etiologic agent.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Arabinonucleosides / adverse effects. Drug-Induced Liver Injury / etiology. Lymphoma, T-Cell / drug therapy. Mediastinal Neoplasms / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19225230.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 60158CV180 / nelarabine
  •  go-up   go-down


25. Tobinai K, Takeyama K, Arima F, Aikawa K, Kobayashi T, Hanada S, Kasai M, Ogura M, Sueoka E, Mukai K, Tajima K, Fukuda H, Shirakawa S, Hotta T, Masanori S, Lymphoma Study Group of the Japan Clinical Oncology Group: Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004. Cancer Sci; 2007 Sep;98(9):1350-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of chemotherapy and stem cell transplantation for adult acute lymphoblastic leukemia or lymphoblastic lymphoma: Japan Clinical Oncology Group Study 9004.
  • Granulocyte colony-stimulating factor (G-CSF)-supported, post-remission chemotherapy (Cx) for adult acute lymphoblastic leukemia (ALL) or lymphoblastic lymphoma (LBL) was evaluated.
  • The median survival time of the 143 eligible patients was 26 months (95% confidence interval, 19-34).
  • At a median follow-up time of 9 years, the 5-year survival rate was 32% and the 5-year progression-free survival (PFS) rate was 26%.
  • The 5-year survival rate of 36 patients who underwent autologous (n = 20) or allogeneic stem cell transplantation (SCT; n = 16) in the first CR group was 58%.
  • In conclusion, G-CSF-supported, intensive post-remission Cx and subsequent SCT are worthy of further investigation for the treatment of adult ALL and LBL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Stem Cell Transplantation
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Adult. Aged. Antimetabolites, Antineoplastic / administration & dosage. Combined Modality Therapy. Cytarabine / administration & dosage. Etoposide / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Male. Methotrexate / administration & dosage. Middle Aged. Mitoxantrone / administration & dosage. Transplantation, Autologous

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. NOVANTRONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17640299.001).
  • [ISSN] 1347-9032
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 6PLQ3CP4P3 / Etoposide; BZ114NVM5P / Mitoxantrone; E7WED276I5 / 6-Mercaptopurine; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


26. Liu KH, Wu CJ, Chou CH, Lee HC, Lee NY, Hung ST, Ko WC: Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol; 2004 Dec;42(12):5950-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We present a case of candidal meningitis refractory to systemic antifungal therapy (amphotericin B and fluconazole).
  • A 63-year-old female with lymphoblastic lymphoma and myelodysplasia with leukemia transformation developed prolonged fever and headache on the seventh day following intrathecal prophylactic chemotherapy.
  • The clinical course was complicated by brain edema, subarachnoid hemorrhage, and hydrocephalus.
  • Parenteral therapy with amphotericin B alone or amphotericin B in combination with fluconazole or intrathecal administration of amphotericin B failed to eradicate C. albicans in the cerebrospinal fluid.
  • After 7 days of caspofungin therapy, however, the cerebrospinal fluid became sterile and the patient gradually regained consciousness.
  • She was discharged 1 month after completing 4 weeks of caspofungin therapy.
  • Second, there is a potential therapeutic benefit of caspofungin in treating a fungal infection of the central nervous system.
  • [MeSH-major] Antifungal Agents / therapeutic use. Candida albicans / isolation & purification. Candidiasis / drug therapy. Immunocompromised Host. Meningitis, Fungal / drug therapy. Peptides, Cyclic / therapeutic use
  • [MeSH-minor] Echinocandins. Female. Humans. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • Hazardous Substances Data Bank. CASPOFUNGIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Diagn Microbiol Infect Dis. 2000 Jul;37(3):169-79 [10904190.001]
  • [Cites] Semin Neurol. 2000;20(3):307-22 [11051295.001]
  • [Cites] Antimicrob Agents Chemother. 2002 Nov;46(11):3634-6 [12384379.001]
  • [Cites] J Microbiol Immunol Infect. 2002 Dec;35(4):249-54 [12542251.001]
  • [Cites] J Antimicrob Chemother. 2003 Jun;51(6):1427-9 [12716772.001]
  • [Cites] Clin Infect Dis. 2003 Jun 1;36(11):1445-57 [12766841.001]
  • [Cites] Clin Infect Dis. 1999 May;28(5):1139-47 [10452649.001]
  • [Cites] Clin Infect Dis. 2004 Jan 15;38(2):161-89 [14699449.001]
  • [Cites] Antimicrob Agents Chemother. 1994 Jan;38(1):83-9 [7511361.001]
  • [Cites] Clin Infect Dis. 1994 Jul;19(1):60-6 [7948559.001]
  • [Cites] Clin Infect Dis. 1995 Aug;21(2):323-7 [8562739.001]
  • [Cites] Clin Infect Dis. 1997 Sep;25(3):673-6 [9314460.001]
  • [Cites] Arch Pathol Lab Med. 1998 Nov;122(11):1030-3 [9822135.001]
  • [Cites] Eur J Clin Microbiol Infect Dis. 2003 Sep;22(9):575-6 [12938012.001]
  • (PMID = 15583351.001).
  • [ISSN] 0095-1137
  • [Journal-full-title] Journal of clinical microbiology
  • [ISO-abbreviation] J. Clin. Microbiol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antifungal Agents; 0 / Echinocandins; 0 / Peptides, Cyclic; F0XDI6ZL63 / caspofungin
  • [Other-IDs] NLM/ PMC535248
  •  go-up   go-down


27. Karube K, Ohshima K, Tsuchiya T, Yamaguchi T, Suefuji H, Suzumiya J, Harada M, Kikuchi M: Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification. Am J Surg Pathol; 2003 Oct;27(10):1366-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Non-B, non-T neoplasms with lymphoblast morphology: further clarification and classification.
  • We studied the morphologic, immunohistochemical, and clinical characteristics of 158 cases of lymphoblastic lymphoma.
  • Based on immunophenotyping and cell lineage, cases were classified into B-cell type (CD20,CD19 or CD79a+, n = 53), T-cell type (surface CD3+, n = 84), and non-B, non-T type (B cell marker- and surface CD3-, n = 21).
  • 1) CD7+ stem cell lymphoma (CD7+SCL) [CD4-, CD7+, CD33+/-, CD56-], 2) blastic natural killer cell lymphoma (B-NKL) [CD4-, CD7+/-, CD33-, CD56+, CD123-], 3) myeloid/NK precursor cell leukemia (M/NKL) [CD4-, CD7+, CD33+, CD56+], and 4) CD4+CD56+ hematodermic malignancy (CD4+CD56+) type [CD4+, CD7+/-, CD33-, CD56+, CD123+].
  • The CD7+SCL and M/NKL types frequently exhibited bone marrow invasion and mediastinal masses.
  • All CD4+CD56+ types were associated with skin lesions.
  • B-NKL type is included into Blastic NK lymphoma in new World Health Organization classification with CD4+CD56+ type.
  • But the cases of B-NKL were more reminiscent of CD7+SCL or M/NKL type than the CD4+CD56+ type, both clinically and histologically.
  • We propose that blastic NK lymphoma, a disease entity in the new WHO classification, should be divided into two types based on phenotypes and clinical features.
  • The non-B, non-T lymphomas exhibited poorer prognoses, similar to that of B-cell lymphomas, than T-cell type tumors (P = 0.009).
  • Among the 21 tumors, the prognosis of the four subtypes did not differ significantly; however, cases receiving aggressive chemotherapy and stem cell transplantation had a more favorable prognosis than those receiving only traditional chemotherapy and radiation therapy (P = 0.0089).
  • [MeSH-major] Antigens, CD / immunology. Lymphocytes / immunology. Myeloid Cells / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / classification. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols. Child. Child, Preschool. Female. Humans. Immunohistochemistry. Lymphoma, Non-Hodgkin / classification. Lymphoma, Non-Hodgkin / immunology. Lymphoma, Non-Hodgkin / pathology. Lymphoma, Non-Hodgkin / therapy. Male. Middle Aged. Stem Cell Transplantation. Survival Analysis. Treatment Outcome

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2004 Jun;28(6):835-7; author reply 837 [15166681.001]
  • (PMID = 14508398.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD
  •  go-up   go-down


28. Song KW, Barnett MJ, Gascoyne RD, Chhanabhai M, Forrest DL, Hogge DE, Lavoie JC, Nantel SH, Nevill TJ, Shepherd JD, Smith CA, Sutherland HJ, Toze CL, Voss NJ, Connors JM: Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes. Ann Oncol; 2007 Mar;18(3):535-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary therapy for adults with T-cell lymphoblastic lymphoma with hematopoietic stem-cell transplantation results in favorable outcomes.
  • BACKGROUND: Controversy exists regarding the role of high-dose therapy followed by stem-cell transplant (SCT) in the treatment of T-cell lymphoblastic lymphoma (T-LBL).
  • We conducted an intention-to-treat analysis of the strategy of SCT as definitive treatment of T-LBL.
  • PATIENTS AND METHODS: From July 1987 to March 2005, 34 adults with T-LBL were diagnosed and treated in British Columbia.
  • Treatment, before planned SCT, consisted of a non-Hodgkin's lymphoma (NHL)/acute lymphoblastic leukemia hybrid chemotherapy protocol (28 patients) or a standard NHL chemotherapy regimen (six patients).
  • All patients who received allografts are alive without disease at 38-141 months since diagnosis.
  • CONCLUSION: A treatment strategy for adults with chemosensitive T-LBL that includes planned consolidation with SCT in first response produces favorable long-term outcome.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17158775.001).
  • [ISSN] 0923-7534
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


29. Sweetenham JW, Santini G, Qian W, Guelfi M, Schmitz N, Simnett S, Nagler A, Holte H, Kvaloy S, Bruzzi P, Goldstone AH: High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group. J Clin Oncol; 2001 Jun 01;19(11):2927-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High-dose therapy and autologous stem-cell transplantation versus conventional-dose consolidation/maintenance therapy as postremission therapy for adult patients with lymphoblastic lymphoma: results of a randomized trial of the European Group for Blood and Marrow Transplantation and the United Kingdom Lymphoma Group.
  • PURPOSE: To determine whether a combination of high-dose therapy and autologous stem-cell transplantation (ASCT) is superior to conventional-dose consolidation and maintenance chemotherapy as postremission therapy in adults with lymphoblastic lymphoma.
  • Patients received standard remission induction therapy, and responding patients were randomized either to continue with a conventional consolidation/maintenance protocol (CC) or to receive high-dose therapy and ASCT.
  • RESULTS: Of the 119 patients entered, 111 were assessable for response to induction therapy.
  • Reasons for failure to randomize included patient refusal (12 patients), early progression or death on induction therapy (eight patients), excessive toxicity of induction regimen (six patients), and elective allogeneic BMT (12 patients).
  • With a median follow-up of 37 months, the actuarial 3-year relapse-free survival rate is 24% for the CC arm and 55% for the ASCT arm (hazards ratio = 0.55 in favor of the ASCT arm; 95% confidence interval [CI], 0.29 to 1.04; P =.065).
  • CONCLUSION: The use of ASCT in adults with lymphoblastic lymphoma in first remission produced a trend for improved relapse-free survival but did not improve overall survival compared with conventional-dose therapy in this small randomized trial.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Bone Marrow Transplantation. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Humans. Male. Middle Aged. Prospective Studies. Transplantation, Autologous. Transplantation, Homologous. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11387366.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  •  go-up   go-down


30. Drevet C, Rosenau L, François S, Monrigal C, Lebouvier B, Foussard C, Geneviève F, Descamps P, Ifrah N: [Management of lymphoblastic lymphomas during pregnancy]. J Gynecol Obstet Biol Reprod (Paris); 2000 Feb;29(1):22-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management of lymphoblastic lymphomas during pregnancy].
  • [Transliterated title] Prise en charge des lymphomes lymphoblastiques au cours de la grossesse.
  • Lymphoblastic lymphoma (non-Hodgkin lymphoma) is a highly uncommon but serious condition during pregnancy.
  • Chemotherapy must be initiated rapidly, during pregnancy.
  • During the first trimester, medical termination should be proposed in order to initiate chemotherapy cannot be started until the second trimester using alkaloids.
  • Chemotherapy has little effect on the fetus during the second trimester.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Pregnancy Complications, Neoplastic / drug therapy
  • [MeSH-minor] Abortion, Therapeutic. Female. Fetus / drug effects. Humans. Patient Care Team / organization & administration. Pregnancy. Pregnancy Outcome. Prognosis. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pregnancy.
  • MedlinePlus Health Information. consumer health - Tumors and Pregnancy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10675830.001).
  • [ISSN] 0368-2315
  • [Journal-full-title] Journal de gynécologie, obstétrique et biologie de la reproduction
  • [ISO-abbreviation] J Gynecol Obstet Biol Reprod (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] FRANCE
  • [Number-of-references] 29
  •  go-up   go-down


31. Seshadri T, Hourigan MJ, Wolf M, Mollee PN, Seymour JF: The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function. Leuk Res; 2006 Apr;30(4):483-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The effect of the Hyper-CVAD chemotherapy regimen on fertility and ovarian function.
  • Hyper-CVAD is a dose intensive chemotherapy regimen that has been used successfully in lymphoblastic lymphoma and leukaemia.
  • Thus, we undertook a retrospective analysis of patients under 40 years of age who had Hyper-CVAD as initial therapy and documented ovarian function as defined by regular menstruation off hormonal agents or naturally conceiving.
  • In conclusion, resumption of normal fertility is probable post-treatment with Hyper-CVAD.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Fertility / drug effects. Leukemia / drug therapy. Ovary / drug effects. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16171861.001).
  • [ISSN] 0145-2126
  • [Journal-full-title] Leukemia research
  • [ISO-abbreviation] Leuk. Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


32. Buie LW, Epstein SS, Lindley CM: Nelarabine: a novel purine antimetabolite antineoplastic agent. Clin Ther; 2007 Sep;29(9):1887-99
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Nelarabine was approved by the US Food and Drug Administration (FDA) in October 2005 for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.
  • Also reviewed are nelarabine's clinical efficacy in T-ALL, T-LBL, and other hematologic malignancies; its toxicity profile, dosage, and administration; and areas of ongoing and future research.
  • Nelarabine has activity in T-cell malignancies, as evaluated in 2 Phase I and 5 Phase II studies.
  • In PGAA 2001, patients with T-ALL in first relapse (n = 33) had an objective response rate of 55% (16 with a complete response [CR] and 2 with a partial response [PR]), and those with T-ALL in second relapse (n = 30) had an objective response rate of 27% (7 CR and 1 PR).
  • Among patients with central nervous system-positive T-ALL or T-cell non-Hodgkins lymphoma (T-NHL) (n = 21), 33% had an objective response (5 CR and 2 PR); among patients with T-ALL or T-NHL with extramedullary relapse (n = 22), 14% had a PR.
  • CALGB 19801 included 39 adult patients with T-cell malignancies, of whom 7 (18%) had a CR and an additional 2 (5%) had a CR without full hematologic recovery.
  • CONCLUSIONS: Nelarabine is indicated for the treatment of T-ALL and T-LBL that has not responded to or has relapsed after treatment with at least 2 chemotherapy regimens.
  • Objective response rates in Phase II clinical trials of nelarabine have ranged from 11% to 60%.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Arabinonucleosides / therapeutic use. Hematologic Neoplasms / drug therapy. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Lymphoma, T-Cell / drug therapy. Purine Nucleosides / therapeutic use
  • [MeSH-minor] Drug Resistance, Neoplasm. Humans

  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18035189.001).
  • [ISSN] 0149-2918
  • [Journal-full-title] Clinical therapeutics
  • [ISO-abbreviation] Clin Ther
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Arabinonucleosides; 0 / Purine Nucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 29
  •  go-up   go-down


33. Korycka A, Lech-Marańda E, Robak T: Novel purine nucleoside analogues for hematological malignancies. Recent Pat Anticancer Drug Discov; 2008 Jun;3(2):123-36
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Recently, the search for more effective and safer antineoplastic agents has led to synthesis and introduction into preclinical and clinical studies of a few new purine nucleoside analogues (PNA).
  • Three of them: clofarabine (CAFdA), nelarabine, and forodesine (immucillin H, BCX-1777), despite belonging to the same group of drugs such as PNA, have shown some differences concerning their active forms, metabolic properties and mechanism of action.
  • However, all these drugs have demonstrated promising activity in patients with relapsed and refractory acute lymphoblastic leukemia (ALL).
  • CAFdA was approved for the therapy of relapsed or refractory ALL in the third line of treatment.
  • It has proved promising in pediatric patients as well as in some patients who are able to proceed to allogenic hematopietic stem cell transplantation (HSCT).
  • Moreover, the drug exhibits an efficacy in acute myeloid leukemia (AML), blast crisis of chronic myelogenous leukemia (CML-BP) and myelodysplastic syndrome (MDS).
  • Nelarabine is recommended for T-ALL and T-cell lymphoblastic lymphoma (T-LBL) with the overall response rates ranging from 11 to 60%.
  • However, the use of the drug is limited by potentially severe neurotoxicity.
  • Forodesine is a purine nucleoside phosphorylase (PNP) inhibitor and it has shown activity in relapsed and refractory T- and B-cells leukemias as well as in cutaneous T-cell lymphoma (CTCL).
  • Great hopes are currently set on the use of these drugs in the treatment of lymphoid and myeloid malignancies in adult and in pediatric patients, however ongoing studies will help to define their role in the standard therapy.
  • [MeSH-major] Adenine Nucleotides / therapeutic use. Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Hematologic Neoplasms / drug therapy. Purine Nucleosides / therapeutic use. Pyrimidinones / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Humans

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18537755.001).
  • [ISSN] 1574-8928
  • [Journal-full-title] Recent patents on anti-cancer drug discovery
  • [ISO-abbreviation] Recent Pat Anticancer Drug Discov
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United Arab Emirates
  • [Chemical-registry-number] 0 / Adenine Nucleotides; 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 0 / Purine Nucleosides; 0 / Pyrimidinones; 426X066ELK / forodesine; 60158CV180 / nelarabine; 762RDY0Y2H / clofarabine
  • [Number-of-references] 102
  •  go-up   go-down


34. Kojima M, Tomita N, Fujimaki K, Fujisawa S, Kanamori H, Ishigatsubo Y: [Lymphoblastic lymphoma presenting as a solitary subcutaneous mass]. Rinsho Ketsueki; 2003 Jan;44(1):25-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphoblastic lymphoma presenting as a solitary subcutaneous mass].
  • A solitary cutaneous or subcutaneous mass in lymphoblastic lymphoma (LBL) is a rare manifestation.
  • A 15-year-old girl presented with a subcutaneous LBL on her left back.
  • Complete remission (CR) was achieved after 2 courses of ACOMP-B (doxorubicin, cyclophosphamide, vincristine, methotrexate, prednisolone, and bleomycin) therapy.
  • Two courses of the chemotherapy and 4 sessions of prophylactic intrathecal methotrexate (15 mg/body) and hydrocortisone (25 mg/body) were added after CR.
  • It is necessary to accumulate more experience with this kind of case to find the appropriate treatment strategy for solitary cutaneous or subcutaneous LBL.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Back. Female. Humans. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12649834.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


35. Bennett CL, Stinson TJ, Lane D, Amylon M, Land VJ, Laver JH: Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. Med Pediatr Oncol; 2000 Feb;34(2):92-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials.
  • BACKGROUND: Growth factor use has been shown to ameliorate chemotherapy-induced neutropenia, leading to shorter hospital stays and lower use of parenteral antibiotics, two costly areas of cancer treatment.
  • In this study a retrospective analysis compared the costs of inpatient supportive care for pediatric patients with T-cell leukemia and advanced lymphoblastic lymphoma enrolled in a Pediatric Oncology Group trial.
  • PROCEDURE: Patients 1-22 years of age were randomized to receive either granulocyte colony-stimulating factor (G-CSF; n = 45) or no G-CSF (n = 43) following induction and two cycles of maintenance therapy.
  • During maintenance therapy, G-CSF patients had significantly fewer days to an ANC >500 cells/microl and a trend towards fewer days of hospitalization.
  • [MeSH-major] Granulocyte Colony-Stimulating Factor / economics. Granulocyte Colony-Stimulating Factor / therapeutic use. Leukemia, T-Cell / drug therapy. Neutropenia / prevention & control. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Pediatric T-cell leukemia.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Filgrastim .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10657867.001).
  • [ISSN] 0098-1532
  • [Journal-full-title] Medical and pediatric oncology
  • [ISO-abbreviation] Med. Pediatr. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA30969; United States / NCI NIH HHS / CA / CA33603; United States / NCI NIH HHS / CA / CA69177
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] UNITED STATES
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Recombinant Proteins; 143011-72-7 / Granulocyte Colony-Stimulating Factor; PVI5M0M1GW / Filgrastim
  •  go-up   go-down


36. Barrionuevo C, Anderson VM, Zevallos-Giampietri E, Zaharia M, Misad O, Bravo F, Cáceres H, Taxa L, Martínez MT, Wachtel A, Piris MA: Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru. Appl Immunohistochem Mol Morphol; 2002 Mar;10(1):7-14
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hydroa-like cutaneous T-cell lymphoma: a clinicopathologic and molecular genetic study of 16 pediatric cases from Peru.
  • Hydroa-like cutaneous T-cell lymphoma (hydroa-like CTCL) is an unusual pediatric malignancy with a poor prognosis.
  • The lesion consists of lymphomatous T-cell infiltration of the skin and subcutis with variable exocytosis and angiocentricity.
  • It has been also called edematous, scarring vasculitic panniculitis and hydroa-like lymphoma.
  • The differential diagnosis includes other cutaneous lymphomas, particularly the cutaneous nasal type T/natural killer-cell lymphoma, mycosis fungoides, precursor T-cell lymphoblastic lymphoma, nonspecific peripheral T-cell lymphoma, cutaneous anaplastic large cell lymphoma, and subcutaneous panniculitic T-cell lymphoma.
  • Chemotherapy and/or radiotherapy had little or no benefit.
  • The lymphoma extended from the epidermis to the subcutis, with frequent angiocentric and periadnexal array.
  • Lymphoma cells were mostly of intermediate size with dense hyperchromatic nuclei, inconspicuous nucleoli, and infrequent mitosis.
  • The lymphoma cells displayed T-cell cytotoxic phenotype.
  • In addition, they were negative for the natural killer cell antigens CD56 and CD57.
  • T-cell receptor gamma (TCRgamma) displayed monoclonal-type rearrangement in four cases studied.
  • Consequently, it should be considered an independent subset of CTCLs and be included as such in the classification of neoplastic diseases of the lymphoid tissues.

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11893040.001).
  • [ISSN] 1541-2016
  • [Journal-full-title] Applied immunohistochemistry & molecular morphology : AIMM
  • [ISO-abbreviation] Appl. Immunohistochem. Mol. Morphol.
  • [Language] ENG
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 34
  •  go-up   go-down


37. Pöttgen C, Stuschke M, Stüben G, Schmitz A, Schwechheimer K, Wacker HH, Rauhut F, Kleuker S, Wilhelm H, Grehl S, Fehlings T: Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma. Strahlenther Onkol; 2003 Sep;179(9):626-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma.
  • PURPOSE: To analyze the long-term results following whole brain radiotherapy (WBRT) with sequential intrathecal (i.th.) cytosine arabinoside (Ara-C) +/- intravenous (i.v.
  • ) Ara-C in patients with primary central nervous system lymphoma (PCNSL).
  • All had sporadic PCNSL with proven histology of high-grade CNS lymphoma (twelve diffuse large-cell B-lymphomas, one lymphoblastic lymphoma, one large T-cell lymphoma).
  • Patients were treated with two to four cycles of induction chemotherapy (40 mg/m2 Ara-C i.th.
  • WBRT was administered using 1.8-Gy fractions.
  • Intrathecal chemotherapy was planned afterwards in 4-week intervals for 6 months.
  • RESULTS: Two of four patients who received i.v. and i.th. induction chemotherapy showed progressive disease, and irradiation was started immediately.
  • Six of 14 patients received 50.4 Gy WBRT, four patients had WBRT up to 39.6 Gy followed by a 10.8-Gy boost.
  • Five patients died early during therapy either due to a decline of the general medical condition or progressive disease.
  • They show only slightly impaired neurocognitive functions without clinical relevance.
  • CONCLUSION: This WBRT-based protocol with i.th. meningeal prophylaxis using Ara-C +/- i.v.
  • The value of i.v. chemotherapy is currently being investigated in prospective studies.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Brain Neoplasms / mortality. Brain Neoplasms / therapy. Cytarabine / therapeutic use. Lymphoma / mortality. Lymphoma / therapy
  • [MeSH-minor] Adult. Aged. Cause of Death. Combined Modality Therapy. Confidence Intervals. Dose Fractionation. Female. Follow-Up Studies. Humans. Injections, Intravenous. Injections, Spinal. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / radiotherapy. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / mortality. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, Large-Cell, Anaplastic / drug therapy. Lymphoma, Large-Cell, Anaplastic / mortality. Lymphoma, Large-Cell, Anaplastic / radiotherapy. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / radiotherapy. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / mortality. Precursor Cell Lymphoblastic Leukemia-Lymphoma / radiotherapy. Radiotherapy Dosage. Survival Analysis. Time Factors

  • Genetic Alliance. consumer health - Central Nervous System Lymphoma, Primary.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14628129.001).
  • [ISSN] 0179-7158
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Röntgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine
  •  go-up   go-down


38. Thomas DA, O'Brien S, Cortes J, Giles FJ, Faderl S, Verstovsek S, Ferrajoli A, Koller C, Beran M, Pierce S, Ha CS, Cabanillas F, Keating MJ, Kantarjian H: Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma. Blood; 2004 Sep 15;104(6):1624-30
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome with the hyper-CVAD regimens in lymphoblastic lymphoma.
  • Therapy of lymphoblastic lymphoma (LL) has evolved with use of chemotherapy regimens modeled after those for acute lymphocytic leukemia (ALL).
  • We treated 33 patients with LL with the intensive chemotherapy regimens hyper-CVAD (fractionated cyclophosphamide, vincristine, Adriamycin, and dexamethasone) or modified hyper-CVAD used for ALL at our institution.
  • Induction consolidation was administered with 8 or 9 alternating cycles of chemotherapy over 5 to 6 months with intrathecal chemotherapy prophylaxis, followed by maintenance therapy.
  • Consolidative radiation therapy was given to patients with mediastinal disease at presentation.
  • No consolidation with autologous or allogeneic stem cell transplantation was performed.
  • At diagnosis, 80% were T-cell immunophenotype, 70% were stages III to IV, 70% had mediastinal involvement, and 9% had central nervous system (CNS) disease.
  • Estimates for the patients with known T-cell immunophenotype were 62% and 67%, respectively.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Dexamethasone / therapeutic use. Doxorubicin / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Female. Humans. Male. Middle Aged. Prognosis. Salvage Therapy. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15178574.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


39. Uner AH, Abali H, Engin H, Akyol A, Ruacan S, Tan E, Güllü I, Altundağ K, Güler N: Myasthenia gravis and lymphoblastic lymphoma involving the thymus: a rare association. Leuk Lymphoma; 2001 Jul;42(3):527-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Myasthenia gravis and lymphoblastic lymphoma involving the thymus: a rare association.
  • In particular, very few cases of lymphoblastic lymphoma involving the thymus and MG have been reported.
  • Here we report a case T-cell lymphoblastic lymphoma involving the thymus who developed MG after the initial diagnosis.
  • The patient initially presented with a mediastinal mass which was diagnosed as lymphoblastic lymphoma.
  • MG was diagnosed during leukemic relapse in this patient and was based on clinical presentation and neurophysiologic studies including single fiber electromyography (EMG) and repetitive nerve stimulation tests.
  • In contrast to the other cases with such an association, the myasthenic symptoms presented nine months after the diagnosis of lymphoma by thymectomy.
  • The patient had a highly aggressive clinical course and was resistant to various chemotherapy regimens.
  • [MeSH-major] Myasthenia Gravis / etiology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Thymus Neoplasms / complications


40. Das DK: Serous effusions in malignant lymphomas: a review. Diagn Cytopathol; 2006 May;34(5):335-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Serous effusions in malignant lymphomas: a review.
  • Although the frequency of pleural effusion is 20-30% in non-Hodgkin's lymphoma (NHL) and Hodgkin's disease (HD), the involvement of peritoneal and pericardial cavities is uncommon.
  • Among lymphoma subtypes, T-cell neoplasms, especially the lymphoblastic lymphomas, more frequently involve the serous fluids.
  • Cytologic features of specific lymphoma subtypes such as lymphoblastic lymphoma, follicular center cell lymphoma, including Burkitt-type lymphoma, marginal zone lymphoma, MALT lymphoma, and anaplastic large-cell lymphoma, etc., have been described in the literature.
  • The differential diagnostic problems of lymphomas in serous effusions include reactive lymphocytoses, early involvement by lymphomatous process, small round-cell tumors (SRCT), and presence of look-alike of Reed-Sternberg cells.
  • ICC not only distinguishes lymphomas from reactive lymphocytoses and SRCTs, it significantly modifies the morphologic diagnosis to achieve a better classification of lymphomas.
  • Morphometry also distinguishes reactive lymphocytoses from malignant lymphoma with a high degree of sensitivity (>85%) and specificity (>95%).
  • This body cavity based lymphoma (BCBL) is a distinct clinicopathologic entity and is found predominantly in AIDS patients with preexisting Kaposi sarcoma.
  • Cytomorphologically, PEL is usually a large-cell lymphoma, which appears to bridge features of large-cell immunoblastic and anaplastic large-cell lymphoma (ALCL).
  • Most of these cases comprise a unique subgroup of B-cell lymphoma, with features of both high-grade anaplastic and B-immunoblastic lymphoma, but T-cell and/or natural killer cell immunophenotypes are described.
  • The presence of pleural effusion at the time of presentation is not only associated with extremely poor outcome of lymphomas, it is also a predictor of disease relapse after chemotherapy and decreased survival.
  • When the patients of lymphomatous pleural effusions with and without mediastinal mass present in respiratory distress, thoracocentesis is the initial diagnostic and therapeutic choice in these patients.
  • In such situations, cytology along with ancillary studies not only gives a quick diagnosis of lymphoma, but also offers prognostically significant information such as classification of lymphomas, its grade and immunophenotype, and presence/absence of viral DNAs and tumor lysis syndrome.
  • [MeSH-major] Cytodiagnosis / methods. Lymphoma / complications. Pleural Effusion, Malignant / etiology
  • [MeSH-minor] Ascitic Fluid / pathology. Carcinoma, Small Cell / pathology. Diagnosis, Differential. Female. Hodgkin Disease / pathology. Humans. Immunophenotyping. Lymphocytosis / pathology. Male. Pericardial Effusion / etiology. Pericardial Effusion / pathology. Reed-Sternberg Cells / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16604559.001).
  • [ISSN] 8755-1039
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 136
  •  go-up   go-down


41. Burkhardt B, Woessmann W, Zimmermann M, Kontny U, Vormoor J, Doerffel W, Mann G, Henze G, Niggli F, Ludwig WD, Janssen D, Riehm H, Schrappe M, Reiter A: Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma. J Clin Oncol; 2006 Jan 20;24(3):491-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impact of cranial radiotherapy on central nervous system prophylaxis in children and adolescents with central nervous system-negative stage III or IV lymphoblastic lymphoma.
  • PURPOSE: In the Non-Hodgkin's Lymphoma-Berlin-Frankfurt-Munster (NHL-BFM) 95 trial, we tested, against the historical control of the combined trials NHL-BFM90 and NHL-BFM86, whether prophylactic cranial radiotherapy (PCRT) can be omitted for CNS-negative patients with stage III or IV lymphoblastic lymphoma (LBL) with sufficient early response.
  • PATIENTS AND METHODS: Apart from the removal of PCRT in NHL-BFM95, the chemotherapy of the three trials was identical except for the amount of l-asparaginase and daunorubicin during induction.
  • The therapy in NHL-BFM95 was accepted to be noninferior when compared with trials NHL-BFM90/86 if the lower limit of the one-sided 95% CI for the difference in the 2-year probability of event-free-survival (pEFS) between target patients of NHL-BFM95 and the historical controls of NHL-BFM90/86 did not exceed -14%.
  • The target patient group consisted of stage III and IV patients who were CNS negative and responded well to induction therapy.
  • For the target group, the pEFS rates at 2 and 5 years were 86% +/- 3% and 82% +/- 3%, respectively, in NHL-BFM95 (median follow-up time, 5.1 years; range, 2.1 to 9.1 years) compared with 91% +/- 2% and 88% +/- 3%, respectively in NHL-BFM90/86 (median follow-up time, 10.7 years; range, 5 to 15.4 years).
  • CONCLUSION: For CNS-negative patients with stage III or IV LBL and sufficient response to induction therapy, treatment without PCRT may be noninferior to treatment including PCRT.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Brain Neoplasms / prevention & control. Cranial Irradiation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Adolescent. Asparaginase / administration & dosage. Child. Daunorubicin / administration & dosage. Disease-Free Survival. Female. Humans. Male. Neoplasm Staging. Remission Induction. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16421426.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.5.1.1 / Asparaginase; ZS7284E0ZP / Daunorubicin
  •  go-up   go-down


42. Hoelzer D, Gökbuget N: Treatment of lymphoblastic lymphoma in adults. Best Pract Res Clin Haematol; 2002 Dec;15(4):713-28
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of lymphoblastic lymphoma in adults.
  • Lymphoblastic lymphoma (LBL) is a rare subtype of non-Hodgkin's lymphoma (NHL) with biological features similar to those of acute lymphoblastic leukaemia.
  • In the majority of cases LBL shows a T-cell phenotype, and mediastinal tumours are the most frequent manifestation.
  • Outcomes of LBL patients treated according to NHL or ALL-type regimens are reviewed.
  • Since prophylaxis of CNS relapse and local recurrence emerged as important issues in the treatment of LBL the different options are discussed.
  • Several studies have used autologous stem cell transplantation (SCT) in the primary treatment of LBL and results are reviewed.
  • The analysis of published prognostic factors and models in LBL demonstrates that, at present, no convincing risk model is available for LBL treated according to contemporary intensive chemotherapy protocols.
  • Future prospects for improvement of treatment results in LBL include intensification of chemotherapy, definition of prognostic factors, evaluation of minimal residual disease and SCT in high-risk patients.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Humans. Mediastinal Neoplasms / radiotherapy. Prognosis. Salvage Therapy. Stem Cell Transplantation. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12617872.001).
  • [ISSN] 1521-6926
  • [Journal-full-title] Best practice & research. Clinical haematology
  • [ISO-abbreviation] Best Pract Res Clin Haematol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 62
  •  go-up   go-down


43. Cairo MS, Raetz E, Lim MS, Davenport V, Perkins SL: Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future. Pediatr Blood Cancer; 2005 Nov;45(6):753-69
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Childhood and adolescent non-Hodgkin lymphoma: new insights in biology and critical challenges for the future.
  • Pediatric non-Hodgkin lymphoma (NHL) is a common and fascinating group of diseases with distinctive underlying genetic events that characterize the major histologic subtypes: diffuse large B-cell lymphoma, Burkitt lymphoma, anaplastic large cell lymphoma and lymphoblastic lymphoma.
  • With systematic improvements in therapy over recent decades, the vast majority of children with NHL of all subtypes are now cured.
  • As is the case with other pediatric malignancies, growing emphasis is now being placed on the development of less toxic, targeted therapeutic approaches, and this review highlights some of the biological discoveries that will potentially open these avenues.
  • [MeSH-major] Lymphoma, Non-Hodgkin / pathology
  • [MeSH-minor] Adolescent. Child. Drug Delivery Systems. Forecasting. Gene Expression Profiling. Humans. Neoplasm Proteins / drug effects


44. Jabbour E, Koscielny S, Sebban C, Peslin N, Patte C, Gargi T, Biron P, Fermé C, Bourhis JH, Vantelon JM, Arnaud P, Ribrag V: High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL). Leukemia; 2006 May;20(5):814-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
  • The most appropriate treatment for lymphoblastic lymphomas (LL) remains uncertain.
  • We treated 27 patients with newly diagnosed LL according to an LMT-89 protocol, which is a modified version of the LMT-81 protocol previously reported in pediatric patients.
  • Complete remission (CR) was achieved in 20/27 patients, unconfirmed complete remission in three patients (residual mediastinal lesion on computed tomography scan) and four failed induction therapy (ORR: 85%).
  • Twelve patients (44%) remained in continuous CR with a median follow-up of 95 months.
  • Bone marrow involvement was associated with a poor outcome.
  • This LMT-89 protocol is a safe regimen and is highly effective in advanced LL without bone marrow involvement.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Bone Marrow / pathology. Disease Progression. Disease-Free Survival. Dose-Response Relationship, Drug. Female. Follow-Up Studies. Humans. Male. Middle Aged. Predictive Value of Tests. Prognosis. Remission Induction. Survival Rate. Treatment Outcome


45. Andersen MK, Christiansen DH, Jensen BA, Ernst P, Hauge G, Pedersen-Bjergaard J: Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992. Br J Haematol; 2001 Sep;114(3):539-43
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Therapy-related acute lymphoblastic leukaemia with MLL rearrangements following DNA topoisomerase II inhibitors, an increasing problem: report on two new cases and review of the literature since 1992.
  • More recently, single cases of acute lymphoblastic leukaemia (ALL), often presenting balanced translocations involving chromosome band 11q23, have been observed.
  • We present two such cases with t(4;11)(q21;q23), one of whom had previously received only single-agent chemotherapy with 4-epi-doxorubicin.
  • A review of the literature since 1992 including these two patients reveals a total of 23 cases of ALL or lymphoblastic lymphoma after chemotherapy presenting balanced translocations to 11q23.
  • All 23 patients had previously received at least one topoisomerase II inhibitor, and in two patients 4-epi-doxorubicin had been administered as single-agent chemotherapy for breast cancer.
  • The MLL gene was found to be rearranged in 14 out of 14 cases, and in three out of six cases the breakpoint was at the telomeric part of the gene, as observed in most cases of AML following therapy with topoisomerase II inhibitors.
  • These results indicate that patients with ALL and balanced translocations to chromosome band 11q23 following chemotherapy with topoisomerase II inhibitors in the future should be included with cases of MDS or AML in calculations of risk of leukaemia.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Doxorubicin / adverse effects. Doxorubicin / analogs & derivatives. Leukemia, Prolymphocytic / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / chemically induced. Proto-Oncogenes. Topoisomerase II Inhibitors. Transcription Factors
  • [MeSH-minor] Adult. Bone Neoplasms / secondary. Breast Neoplasms / drug therapy. Chromosomes, Human, Pair 11. Chromosomes, Human, Pair 4. DNA-Binding Proteins / genetics. Enzyme Inhibitors / adverse effects. Enzyme Inhibitors / therapeutic use. Female. Gene Rearrangement. Histone-Lysine N-Methyltransferase. Humans. Lymphatic Metastasis. Male. Middle Aged. Myeloid-Lymphoid Leukemia Protein. Seminoma / complications. Seminoma / drug therapy. Testicular Neoplasms / complications. Testicular Neoplasms / drug therapy. Translocation, Genetic

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11552977.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / DNA-Binding Proteins; 0 / Enzyme Inhibitors; 0 / MLL protein, human; 0 / Topoisomerase II Inhibitors; 0 / Transcription Factors; 149025-06-9 / Myeloid-Lymphoid Leukemia Protein; 80168379AG / Doxorubicin; EC 2.1.1.43 / Histone-Lysine N-Methyltransferase
  • [Number-of-references] 28
  •  go-up   go-down


46. Jeong W, Seiter K, Strauchen J, Rafael T, Lau HC, Breakstone B, Ahmed T, Liu D: PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma. Leuk Res; 2005 May;29(5):591-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET scan-positive cat scratch disease in a patient with T cell lymphoblastic lymphoma.
  • In patients who have history of lymphoma, a positive positron emission tomography (PET) scan is frequently considered as good evidence for relapse and/or persistent disease.
  • Thus, lymph node biopsy is not always done to confirm the diagnosis of relapse or refractory lymphoma before a patient is subjected to further chemotherapy.
  • We report a case of patient with history of T cell lymphoblastic lymphoma who presented again with inguinal lymphadenopathy and positive study on positron emission tomography suggestive of lymphoma relapse.
  • This case suggests that in the immunocompromised patients who had history of lymphoma, infectious etiology should be ruled out for PET scan-positive lymphadenopathy.
  • [MeSH-major] Afipia. Cat-Scratch Disease / diagnosis. Inguinal Canal / pathology. Lymphatic Diseases / pathology. Lymphoma, T-Cell / diagnosis. Positron-Emission Tomography


47. Bielen D, Mortelé K, Peters H, Lombard D, Ros R: Small bowel obstruction secondary to disseminated candidiasis in an immunocompromised patient: radiologic-pathologic correlation. JBR-BTR; 2005 Jan-Feb;88(1):20-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Immunosuppression for therapeutic reasons (e.g. post transplantation, post chemotherapy), as well as pathologic immunodeficiency due to certain pathologic conditions (e.g.
  • As a result, the concomitant risk for opportunistic infections is higher and immunocompromised patients may present with uncommon clinical and radiologic conditions.
  • We report on a case of a 33-year-old immunocompromised woman with a history of recurrent T-cell lymphoblastic lymphoma, which presented with abdominal pain.
  • Computed tomography (CT) images demonstrated significant small bowel dilatation, wall thickening, and high-density intestinal content, with a focal point of transition in the pelvis.
  • [MeSH-major] Candidiasis / diagnosis. Immunocompromised Host. Intestinal Obstruction / microbiology. Jejunal Diseases / microbiology. Opportunistic Infections / diagnosis
  • [MeSH-minor] Adult. Enteritis / microbiology. Fatal Outcome. Female. Humans. Lymphoma, T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy

  • MedlinePlus Health Information. consumer health - Intestinal Obstruction.
  • MedlinePlus Health Information. consumer health - Small Intestine Disorders.
  • MedlinePlus Health Information. consumer health - Yeast Infections.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15792164.001).
  • [ISSN] 0302-7430
  • [Journal-full-title] JBR-BTR : organe de la Société royale belge de radiologie (SRBR) = orgaan van de Koninklijke Belgische Vereniging voor Radiologie (KBVR)
  • [ISO-abbreviation] JBR-BTR
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Belgium
  •  go-up   go-down


48. Onciu M: Acute lymphoblastic leukemia. Hematol Oncol Clin North Am; 2009 Aug;23(4):655-74
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Acute lymphoblastic leukemia.
  • Acute lymphoblastic leukemia and lymphoblastic lymphoma constitute a family of genetically heterogeneous lymphoid neoplasms derived from B- and T-lymphoid progenitors.
  • Diagnosis is based on morphologic, immunophenotypic, and genetic features that allow differentiation from normal progenitors and other hematopoietic and nonhematopoietic neoplasms.
  • Current intensive chemotherapy regimens have accomplished overall cure rates of 85% to 90% in children and 40% to 50% in adults, with outcomes depending on the genetic subtype of disease and clinical features at presentation.
  • Therapy is optimized using minimal residual disease studies that employ flow cytometric and molecular methodologies, and are important determinants of prognosis.
  • Genetic analyses currently underway are likely to provide insight into biology, mechanisms of relapse, pharmacogenetics, and new potential therapeutic targets, which should aid in further improvement of outcome in this disease.
  • [MeSH-major] Immunophenotyping / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology
  • [MeSH-minor] Diagnosis, Differential. Flow Cytometry. Gene Rearrangement. Humans. Immunoglobulins / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / genetics. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / immunology. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / pathology. Receptors, Antigen, T-Cell / genetics

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19577163.001).
  • [ISSN] 1558-1977
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins; 0 / Receptors, Antigen, T-Cell
  • [Number-of-references] 105
  •  go-up   go-down


49. Winter SS, Holdsworth MT, Devidas M, Raisch DW, Chauvenet A, Ravindranath Y, Ducore JM, Amylon MD: Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296. Pediatr Blood Cancer; 2006 Feb;46(2):179-86
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Antimetabolite-based therapy in childhood T-cell acute lymphoblastic leukemia: a report of POG study 9296.
  • PURPOSE: A previous Pediatric Oncology Group (POG) study showed high incidence of secondary acute myelogenous leukemia (AML) in children treated for T-cell acute lymphoblastic leukemia (T-ALL) or higher-stage lymphoblastic lymphoma.
  • To prevent secondary neoplasms, induce prolonged asparagine depletion, and maintain high event-free survival (EFS) in children with newly diagnosed T-ALL or higher-stage non-Hodgkins lymphoma (NHL), we designed this pilot study to determine feasibility and safety of substituting methotrexate/mercaptopurine for teniposide/cytarabine and PEG-asparaginase for native asparaginase.
  • PATIENTS AND METHODS: Forty-five patients were entered, 29 with T-ALL and 16 with higher-stage NHL.
  • Forty-two of 45 patients achieved complete remission (CR), and 27 completed the therapy in continuous CR.
  • Treatment consisted of 4-week induction then 6 weeks consolidation and ten 9-week maintenance cycles.
  • Therapy primarily comprised antimetabolites, anthracyclines, alkylating agents, and asparaginase.
  • Expected chemotherapy duration was 100 weeks.
  • RESULTS: Forty-two of 45 patients achieved CR, and 27 completed therapy.
  • Five-year EFS was 68.5% (SE 9.1%) for T-ALL and 81.3% (SE 9.8%) for NHL.
  • Five-year EFS was 73.1% (SE 6.8%) for the entire cohort.
  • No patients treated entirely on this study developed secondary neoplasms.
  • One patient taken off study for asparaginase toxicity was treated with multiagent therapy that contained teniposide, and died from secondary myelodysplasia (sMDS)/AML.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Anthracyclines / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Antineoplastic Agents, Alkylating / administration & dosage. Asparaginase / administration & dosage. Asparaginase / adverse effects. Child. Child, Preschool. Disease-Free Survival. Drug Hypersensitivity / etiology. Female. Follow-Up Studies. Humans. Lymphoma, Non-Hodgkin / drug therapy. Lymphoma, Non-Hodgkin / mortality. Male. Pilot Projects. Remission Induction. Sepsis / etiology. Sepsis / mortality

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16007607.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5 U10 CA5312; United States / NCI NIH HHS / CA / CA29139
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents, Alkylating; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


50. Sandlund JT: Should adolescents with NHL be treated as old children or young adults? Hematology Am Soc Hematol Educ Program; 2007;:297-303
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The SEER (Surveillance, Epidemiology, and End Results) data for the years 1975-1998 show that children with non-Hodgkin lymphoma (NHL) have a better treatment outcome than do adults.
  • Some factors are related to the patient (e.g., drug distribution and clearance, performance status, compliance, sex) whereas others pertain to tumor histology and biology.
  • From ages 5 through 14 years, Burkitt lymphoma is the predominant histologic subtype, whereas diffuse large B-cell lymphoma is most common in the 15- to 29-year age range.
  • Because different treatment strategies are often used in children and adults with NHL, the choice of therapy for adolescents and young adults (ages 15 through 29 years) is challenging and somewhat controversial.
  • It is reasonable to consider pediatric strategies for some adolescents and very young adults with NHL, and pediatric strategies are currently used to treat adults with certain subtypes of NHL (Burkitt lymphoma, lymphoblastic lymphoma).
  • However, the use of pediatric strategies in adults does not guarantee a comparable outcome, as illustrated by trials for adult lymphoblastic lymphoma.
  • Age-related differences in tumor biology have been demonstrated in anaplastic large-cell lymphoma (ALCL) and diffuse large B-cell lymphoma (DLBCL).
  • Additional biologic data will not only improve prognosis and treatment stratification but, more important, will lead to the identification of specific molecular targets for therapy.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18024643.001).
  • [ISSN] 1520-4391
  • [Journal-full-title] Hematology. American Society of Hematology. Education Program
  • [ISO-abbreviation] Hematology Am Soc Hematol Educ Program
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 62
  •  go-up   go-down


51. Thomas D, O'Brien S, Faderl S, Ravandi F, Jabbour E, Pierce S, Cortes J, Kantarjian H: Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen. Cancer; 2010 Oct 1;116(19):4580-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Anthracycline dose intensification in adult acute lymphoblastic leukemia: lack of benefit in the context of the fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone regimen.
  • BACKGROUND: In previous studies of frontline therapy for adult acute lymphoblastic leukemia (ALL), early treatment with higher doses of anthracyclines has been reported to improve outcome.
  • The current study was conducted to evaluate whether addition of anthracycline-based consolidation chemotherapy (Course 2) with liposomal daunorubicin (150 mg/m2 intravenously [IV] on Days 1 and 2) and cytarabine (1.5 g/m2 IV on Days 1 and 2) to the standard hyper-CVAD regimen (fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with high dose methotrexate and cytarabine) would improve outcome.
  • METHODS: Sixty-eight consecutive adults with de novo ALL or lymphoblastic lymphoma were treated with this modified hyper-CVAD regimen inclusive of rituximab for CD20 expression≥20%.
  • With a median follow-up of 90 months, the 5-year CR duration (CRD) and overall survival (OS) rates were 46% and 44%, respectively.
  • CONCLUSIONS: In the context of the hyper-CVAD regimen, early anthracycline intensification did not improve outcome for adults with de novo ALL or lymphoblastic lymphoma.
  • [MeSH-major] Anthracyclines / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Daunorubicin / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Humans. Methotrexate / administration & dosage. Middle Aged. Salvage Therapy. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 American Cancer Society.
  • (PMID = 20572037.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anthracyclines; 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; CVAD protocol
  • [Other-IDs] NLM/ NIHMS652593; NLM/ PMC4458382
  •  go-up   go-down


52. Duval M, Suciu S, Ferster A, Rialland X, Nelken B, Lutz P, Benoit Y, Robert A, Manel AM, Vilmer E, Otten J, Philippe N: Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial. Blood; 2002 Apr 15;99(8):2734-9
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of Escherichia coli-asparaginase with Erwinia-asparaginase in the treatment of childhood lymphoid malignancies: results of a randomized European Organisation for Research and Treatment of Cancer-Children's Leukemia Group phase 3 trial.
  • Asparaginase is an enzyme used in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma in children.
  • Nonrandomized clinical studies have suggested a similar efficacy of these 2 types of asparaginases and a lower toxicity for Erwinia-asparaginase.
  • The European Organisation for Research and Treatment of Cancer-Children's Leukemia Group (EORTC-CLG) 58881 trial randomized 700 children with acute lymphoblastic leukemia or lymphoblastic lymphoma to either E coli- or Erwinia-asparaginase at the same dosage of 10 000 IU/m(2) twice weekly to compare toxicity and efficacy.
  • The estimate of event-free survival rate (SE) at 6 years was 59.8% (2.6%) versus 73.4% (2.4%).
  • With the dose scheduling used in this protocol, E coli-asparaginase induced more coagulation abnormalities but was superior to Erwinia-asparaginase for the treatment of childhood lymphoid malignancies.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Remission Induction / methods. Therapeutic Equivalency

  • Genetic Alliance. consumer health - Childhood Cancer.
  • COS Scholar Universe. author profiles.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11929760.001).
  • [ISSN] 0006-4971
  • [Journal-full-title] Blood
  • [ISO-abbreviation] Blood
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-30
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 3.5.1.1 / Asparaginase
  •  go-up   go-down


53. Shiozawa Y, Kiyokawa N, Fujimura J, Suzuki K, Yarita Y, Fujimoto J, Saito M, Yamashiro Y: Primary malignant lymphoma of the central nervous system in an immunocompetent child: a case report. J Pediatr Hematol Oncol; 2005 Oct;27(10):561-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary malignant lymphoma of the central nervous system in an immunocompetent child: a case report.
  • Primary lymphoma of the central nervous system (PCNSL) is extremely rare, especially in childhood.
  • A 9-year-old Japanese boy was diagnosed as having precursor-B cell-type lymphoblastic lymphoma, based on morphologic and immunocytochemical analysis of mononuclear cells in the cerebrospinal fluid and a positive reaction for terminal deoxynucleotidyl transferase (TdT), CD19, CD79a, and CD179b.
  • After seven courses of chemotherapy and craniospinal radiotherapy, the patient is alive, well, and in continuous complete remission.
  • Despite its rarity, PCNSL should be included in the differential diagnosis in the presence of symptoms of increased intracranial pressure and/or unusual imaging findings of the brain.
  • [MeSH-major] Brain Neoplasms / pathology. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Antigens, CD / cerebrospinal fluid. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. DNA Nucleotidylexotransferase / cerebrospinal fluid. Humans. Immunocompetence. Magnetic Resonance Imaging. Male


54. Sun XF, Jiang WQ, Liu DG, Xia ZJ, Huang HQ, Zhang L, Li YH, Zhou ZM, Zhen ZJ, Xia Y, He YJ, Guan ZZ: [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases]. Ai Zheng; 2004 Dec;23(12):1687-91
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of modified BFM-90 regimen on children and adolescents with T cell lymphoblastic lymphoma: a report of 20 cases].
  • BACKGROUND & OBJECTIVE: T-cell lymphoblastic lymphoma in childhood and adolescence is an aggressive malignant disease with higher mortality.
  • BFM-90 regimen for lymphoblastic lymphoma is one of the most effective regimens.
  • This study was designed to evaluate efficacy and toxicities of modified BFM-90 regimen on Chinese children and adolescents with lymphoblastic lymphoma.
  • METHODS: A total of 20 naive children and adolescents with T cell lymphoblastic lymphoma were enrolled, 7 in stage III, and 13 in stage IV.
  • All patients received modified BFM-90 regimen consisting of induction, consolidation and central nervous system prophylaxis, reinduced alleviation, and maintenance therapy.
  • Total treatment duration was 2 years.
  • Of 2 patients at CR1 received APBSC, 1 relapsed after transplantation, but achieved CR and survived after salvage chemotherapy;1 survived all along.
  • Of other patients achieved CR, 5 relapsed; of these 5 patients, 1 survived after allogeneic stem cell transplantation, 1 survived after autologous stem cell transplantation, 3 died of progressive disease after chemotherapy.
  • CONCLUSIONS: Modified BFM-90 regimen is feasible for Chinese children and adolescent patients with lymphoblastic lymphoma, and may improve survival rate of these patients.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Asparaginase / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Methotrexate / therapeutic use. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Remission Induction. Stem Cell Transplantation. Survival Rate. Treatment Outcome. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15601561.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


55. Cho Y, Suzuki S, Yokoi M, Shimada M, Kuwabara S, Murayama A: Lateral position prevents respiratory occlusion during surgical procedure under general anesthesia in the patient of huge anterior mediastinal lymphoblastic lymphoma. Jpn J Thorac Cardiovasc Surg; 2004 Oct;52(10):476-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lateral position prevents respiratory occlusion during surgical procedure under general anesthesia in the patient of huge anterior mediastinal lymphoblastic lymphoma.
  • Lymphoblastic lymphoma, an aggressive mediastinal mass, is recognized as serious threat to the patient in developing cardiac tamponade or airway obstruction.
  • Surgical procedure is often required to relieve clinical emergency and to establish prompt pathological diagnosis.
  • Pathological diagnosis was precursor T-lymphoblastic lymphoma.
  • There were no complications attributable to the operative procedure.
  • Further chemotherapy reduced the mediastinal mass in size after two weeks when the patient developed sepsis and died.
  • Lateral position prevents respiratory occlusion during surgical procedure under general anesthesia in the patient of huge anterior mediastinal tumor with airway obstruction.
  • [MeSH-major] Airway Obstruction / prevention & control. Anesthesia, General. Cardiac Tamponade / surgery. Mediastinal Neoplasms / surgery. Posture. Precursor Cell Lymphoblastic Leukemia-Lymphoma / surgery
  • [MeSH-minor] Adolescent. Fatal Outcome. Humans. Intubation, Intratracheal. Male. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Guide to Good Posture.
  • MedlinePlus Health Information. consumer health - Pericardial Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg Oncol. 1995 Mar;2(2):165-9 [7728571.001]
  • [Cites] J Surg Oncol. 1985 Sep;30(1):19-22 [4079414.001]
  • [Cites] Ann Fr Anesth Reanim. 1988;7(6):520-3 [3223646.001]
  • [Cites] Mayo Clin Proc. 1988 Oct;63(10 ):1004-11 [3172849.001]
  • [Cites] Cancer. 1982 Dec 1;50(11):2486-92 [7139540.001]
  • [Cites] Clin Radiol. 1986 May;37(3):257-61 [3486737.001]
  • [Cites] Acta Radiol. 1987 Jul-Aug;28(4):403-7 [2958053.001]
  • [Cites] Eur J Cancer Clin Oncol. 1982 Nov;18(11):1131-6 [6891654.001]
  • [Cites] J Cardiovasc Surg (Torino). 1995 Aug;36(4):343-8 [7593144.001]
  • [Cites] Ann Thorac Surg. 1999 Dec;68(6):2324-6 [10617025.001]
  • (PMID = 15552973.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


56. Uyttebroeck A, Suciu S, Laureys G, Robert A, Pacquement H, Ferster A, Marguerite G, Mazingue F, Renard M, Lutz P, Rialland X, Mechinaud F, Cavé H, Baila L, Bertrand Y, Children's Leukaemia Group (CLG) of the European Organisation for Research and Treatment of Cancer (EORTC): Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial. Eur J Cancer; 2008 Apr;44(6):840-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of childhood T-cell lymphoblastic lymphoma according to the strategy for acute lymphoblastic leukaemia, without radiotherapy: long term results of the EORTC CLG 58881 trial.
  • From June 1989 through to November 1998, 121 children with newly diagnosed T-cell lymphoblastic lymphoma (T-LBL) were included in the EORTC 58881 trial conducted by the Children's Leukaemia Group.
  • The therapy regimen was based on a Berlin-Frankfurt-Munster protocol, for a total duration of 24 months.
  • Cranial irradiation, prophylactic cranial and local, was omitted, even for patients with central nervous involvement at diagnosis.
  • The overall event-free survival (EFS) rate at 6 years was 77.5% (standard error (SE)=4%).
  • Median time of relapse was 1 year after complete remission (range 0.2-5.9 years).
  • Overall survival rate at 6 years was 86% (SE=3%).
  • An intensive acute lymphoblastic leukaemia type chemotherapy regimen without irradiation leads to a high cure and survival rate in childhood T-LBL without an increased CNS recurrence.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Humans. Infant. Male. Recurrence. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18342502.001).
  • [ISSN] 0959-8049
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-18; United States / NCI NIH HHS / CA / 5U10-CA11488-19; United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-21; United States / NCI NIH HHS / CA / 5U10-CA11488-22; United States / NCI NIH HHS / CA / 5U10-CA11488-23; United States / NCI NIH HHS / CA / 5U10-CA11488-24; United States / NCI NIH HHS / CA / 5U10-CA11488-25; United States / NCI NIH HHS / CA / 5U10-CA11488-26; United States / NCI NIH HHS / CA / 5U10-CA11488-27; United States / NCI NIH HHS / CA / 5U10-CA11488-28; United States / NCI NIH HHS / CA / 5U10-CA11488-29; United States / NCI NIH HHS / CA / 5U10-CA11488-30; United States / NCI NIH HHS / CA / 5U10-CA11488-31; United States / NCI NIH HHS / CA / 5U10-CA11488-32; United States / NCI NIH HHS / CA / 5U10-CA11488-33; United States / NCI NIH HHS / CA / 5U10-CA11488-34; United States / NCI NIH HHS / CA / 5U10-CA11488-35; United States / NCI NIH HHS / CA / 5U10-CA11488-36
  • [Publication-type] Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Investigator] Philippet P; Otten J; Plouvier E; Béhar C; Boutard P; Millot F; Waterkeyn C; Velde IV; Solbu G
  •  go-up   go-down


57. Cohen MH, Johnson JR, Justice R, Pazdur R: FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma. Oncologist; 2008 Jun;13(6):709-14
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma.
  • PURPOSE: To describe the clinical trials leading to U.S.
  • Food and Drug Administration (FDA) approval of nelarabine (Arranon), a new purine analogue, for the treatment of patients with T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens.
  • Patients were in their first or subsequent relapse and/or were refractory to first-line therapy.
  • Treatments were repeated every 21 days.
  • CR to nelarabine treatment was observed in five patients (13%) and CR+CR* was observed in nine patients (23%).
  • CR to nelarabine treatment was observed in five patients (18%) and CR+CR* was observed in six patients (21%).
  • CONCLUSIONS: On October 28, 2005, the FDA granted accelerated approval for nelarabine for treatment of patients with relapsed or refractory T-ALL/T-LBL after at least two prior regimens.
  • The applicant will conduct postmarketing clinical trials to demonstrate clinical benefit, for example, survival prolongation.
  • [MeSH-major] Arabinonucleosides / therapeutic use. Drug Approval / legislation & jurisprudence. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Clinical Trials, Phase II as Topic. Humans. Infant. Middle Aged. United States. United States Food and Drug Administration

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • SciCrunch. DrugBank: Data: Chemical .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18586926.001).
  • [ISSN] 1083-7159
  • [Journal-full-title] The oncologist
  • [ISO-abbreviation] Oncologist
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Arabinonucleosides; 60158CV180 / nelarabine
  •  go-up   go-down


58. Dettmeyer R, Driever F, Becker A, Wiestler OD, Madea B: Fatal myeloencephalopathy due to accidental intrathecal vincristin administration: a report of two cases. Forensic Sci Int; 2001 Oct 15;122(1):60-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report on two fatal cases of accidental intrathecal vincristine instillation in a 5-year old girl with recurrent acute lymphoblastic leucemia and a 57-year old man with lymphoblastic lymphoma.
  • The clinical course and histopathological results of the two cases are presented.
  • A better controlled regimen for administering vincristine and intrathecal chemotherapy is recommended.
  • [MeSH-major] Antineoplastic Agents, Phytogenic / adverse effects. Encephalomyelitis / chemically induced. Medication Errors. Vincristine / adverse effects
  • [MeSH-minor] Child, Preschool. Fatal Outcome. Female. Humans. Injections, Spinal. Leukemia, Lymphoid / drug therapy. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Medication Errors.
  • Hazardous Substances Data Bank. VINCRISTINE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11587867.001).
  • [ISSN] 0379-0738
  • [Journal-full-title] Forensic science international
  • [ISO-abbreviation] Forensic Sci. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 5J49Q6B70F / Vincristine
  • [Number-of-references] 29
  •  go-up   go-down


59. Mitropoulos FA, Angelopoulou MK, Siakantaris MP, Rassidakis G, Vayiopoulos GA, Papalampros E, Kalovidouris A, Pangalis GA: Primary non-Hodgkin's lymphoma of the gall bladder. Leuk Lymphoma; 2000 Dec;40(1-2):123-31
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary non-Hodgkin's lymphoma of the gall bladder.
  • Primary non-Hodgkin lymphoma of the gallbladder is a very rare location of extranodal non-Hodgkin lymphomas.
  • A patient with a primary non-Hodgkin lymphoma of the gallbladder is reported and in addition, the English literature is reviewed.
  • Clinical presentation, diagnostic evaluation, histopathologic findings, treatment modalities and prognosis of primary gallbladder lymphomas reported up to date are reviewed and discussed.
  • Our patient was diagnosed as a T-cell lymphoblastic lymphoma, after cholecystectomy, and had no evidence of disease elsewhere.
  • She was treated with combination chemotherapy and complete remission was achieved.
  • Review of the literature over a 30-year period revealed only 12 cases of well-documented primary non-Hodgkin lymphoma involvement of the gallbladder, including the present case.
  • Diagnostic investigation included ultrasound of the upper abdomen, computed tomography of the abdomen and pelvis, oral cholecystography, percutaneous cholangiography and endoscopic retrograde cholangiopangreatography.
  • Preoperative diagnosis was established in none of the patients.
  • Treatment modalities included surgery and postoperative chemotherapy and irradiation.
  • Here we document the first reported case of a patient with primary T-cell lymphoblastic non-Hodgkin lymphoma of the gallbladder.
  • Review of the literature shows the existence of non-Hodgkin lymphoma of the gallbladder, its rarity and its general dismal prognosis.
  • [MeSH-major] Gallbladder Neoplasms / diagnosis. Lymphoma, Non-Hodgkin / diagnosis
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cyclophosphamide / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Female. Gallbladder / pathology. Gallbladder / ultrasonography. Gallbladder / ultrastructure. Humans. Methotrexate / administration & dosage. Prednisone / administration & dosage. Vincristine / administration & dosage

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11426613.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; MEVAP protocol
  • [Number-of-references] 33
  •  go-up   go-down


60. Roecker AM, Stockert A, Kisor DF: Nelarabine in the treatment of refractory T-cell malignancies. Clin Med Insights Oncol; 2010 Dec 01;4:133-41
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nelarabine in the treatment of refractory T-cell malignancies.
  • Nelarabine is a nucleoside analog indicated for the treatment of adult and pediatric patients with T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic lymphoma (T-LBL) that is refractory or has relapsed after treatment with at least two chemotherapy regimens.
  • This article will summarize the pharmacologic properties of nelarabine and will address the current place in therapy nelarabine holds based upon the results of the available clinical trials to date.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21151585.001).
  • [ISSN] 1179-5549
  • [Journal-full-title] Clinical Medicine Insights. Oncology
  • [ISO-abbreviation] Clin Med Insights Oncol
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2999959
  • [Keywords] NOTNLM ; Arranon / Atriance / T-cell / leukemia / lymphoma / nelarabine
  •  go-up   go-down


61. O'Connor OA, Toner LE, Vrhovac R, Budak-Alpdogan T, Smith EA, Bergman P: Comparative animal models for the study of lymphohematopoietic tumors: strengths and limitations of present approaches. Leuk Lymphoma; 2005 Jul;46(7):973-92
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Underneath the single term lymphoma exist some of the fastest growing cancers known to science (i.e Burkitt's and lymphoblastic lymphoma), as well as some of the slowest growing (i.e. small lymphocytic lymphoma [SLL] and follicular lymphoma).
  • It is this very biology that can dictate the selection of drugs and treatment approaches for managing these patients, strategies that can range from very aggressive combination chemotherapy administered in an intensive care unit (for example, patients with Burkitt's lymphoma), to watch and wait approaches that may go on for years in patients with SLL.
  • It is precisely this molecular understanding that is beginning to form the basis for a new approach to thinking about lymphoma, and novel approaches to its management.
  • Unfortunately, while our understanding of human lymphoma has blossomed, our ability to generate appropriate animal models reflective of this biology has not.
  • Most preclinical models of these diseases still rely upon sub-cutaneous xenograft models of only the most aggressive lymphomas like Burkitt's lymphoma.
  • While these models clearly serve an important role in understanding biology, and perhaps more importantly, in identifying promising new drugs for these diseases, they fall short in truly representing the broader, more heterogenous biology found in patients.
  • Clearly, depending upon the questions being posed, or the types of drugs being studied, the best model to employ may vary from situation to situation.
  • In this article, we will review the numerous complexities associated with various animal models of lymphoma, and will try to explore several alternative models which might serve as better in vivo.
  • [MeSH-major] Disease Models, Animal. Hematologic Neoplasms / pathology. Lymphoma / pathology

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16019548.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 246
  •  go-up   go-down


62. Moree JS, Bhakta MG, Ledbetter J: Complication of mediastinal mass: acquired tracheoesophageal fistula associated with T-cell lymphoblastic lymphoma. Pediatr Pulmonol; 2006 Jul;41(7):688-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complication of mediastinal mass: acquired tracheoesophageal fistula associated with T-cell lymphoblastic lymphoma.
  • The occurrence of a tracheoesophageal fistula (TEF) in the setting of lymphoma has only rarely been reported in the world literature.
  • Most cases reported were associated with radiation therapy vs. chemotherapy alone.
  • This report presents one case illustrating the difficulty encountered managing a TEF that developed while undergoing chemotherapy for T-cell lymphoblastic lymphoma.
  • [MeSH-major] Mediastinal Neoplasms / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / complications. Tracheoesophageal Fistula / etiology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Tracheoesophageal fistula.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16703600.001).
  • [ISSN] 8755-6863
  • [Journal-full-title] Pediatric pulmonology
  • [ISO-abbreviation] Pediatr. Pulmonol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 9
  •  go-up   go-down


63. Garcia-Manero G, Kantarjian HM: The hyper-CVAD regimen in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am; 2000 Dec;14(6):1381-96, x-xi
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The regimen of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD) has demonstrated significant activity in adult lymphocytic leukemia (ALL) and in other hematologic malignancies, including Burkitt's disease, lymphoblastic lymphoma, mantle cell lymphoma, and multiple myeloma.
  • This article presents the rationale for the development of this regimen, describes the program, summarizes the results of the large clinical trials developed at the University of Texas M. D.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Anti-Infective Agents / administration & dosage. Antibiotic Prophylaxis. Antibodies, Monoclonal / therapeutic use. Antibodies, Monoclonal, Murine-Derived. Biomarkers, Tumor. Central Nervous System Neoplasms / prevention & control. Child. Clinical Trials as Topic. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Dexamethasone / administration & dosage. Dexamethasone / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Drug Administration Schedule. Granulocyte Colony-Stimulating Factor / therapeutic use. Humans. Immunization, Passive. Immunophenotyping. Infusions, Intravenous. Injections, Spinal. Karyotyping. Mercaptopurine / administration & dosage. Methotrexate / administration & dosage. Middle Aged. Philadelphia Chromosome. Prednisone / administration & dosage. Remission Induction. Risk. Rituximab. Survival Analysis. Texas / epidemiology. Treatment Outcome. Vincristine / administration & dosage. Vincristine / adverse effects

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. RITUXIMAB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11147229.001).
  • [ISSN] 0889-8588
  • [Journal-full-title] Hematology/oncology clinics of North America
  • [ISO-abbreviation] Hematol. Oncol. Clin. North Am.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Infective Agents; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Murine-Derived; 0 / Biomarkers, Tumor; 143011-72-7 / Granulocyte Colony-Stimulating Factor; 4F4X42SYQ6 / Rituximab; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / Mercaptopurine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; CVAD protocol; POMP protocol
  • [Number-of-references] 27
  •  go-up   go-down


64. Aljurf M, Zaidi SZ: Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies. Biol Blood Marrow Transplant; 2005 Oct;11(10):739-54
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy and hematopoietic stem cell transplantation for adult T-cell lymphoblastic lymphoma: current status and controversies.
  • Adult T-cell lymphoblastic lymphoma is a relatively rare aggressive type of non-Hodgkin lymphoma with frequent involvement of extranodal sites.
  • Because of the rarity of this malignancy, it is treated variably and often suboptimally, using approaches similar to those used for other types of aggressive non-Hodgkin lymphomas, with the consequence that outcome is often suboptimal.
  • The collective experience in the management of adult T-cell lymphoblastic lymphoma suggests a good outcome for patients with no adverse prognostic factors who are treated with an acute lymphocytic leukemia-like treatment strategy.
  • Patients with adverse prognostic features should be considered for more aggressive therapy-specifically, high-dose chemotherapy and hematopoietic stem cell transplantation.
  • This article will attempt to review the current status of chemotherapy treatment programs and the relative merits of the different hematopoietic stem cell transplantation programs in this disease, particularly in relation to the pathologic and clinical features that correlate with disease prognosis.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Hematopoietic Stem Cell Transplantation / methods. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adult. Central Nervous System Neoplasms / therapy. Graft vs Tumor Effect. Humans. Mediastinal Neoplasms / therapy. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16182175.001).
  • [ISSN] 1083-8791
  • [Journal-full-title] Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • [ISO-abbreviation] Biol. Blood Marrow Transplant.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 114
  •  go-up   go-down


65. Jost LM, Honegger HP, Stahel RA: [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich]. Schweiz Med Wochenschr; 2000 Jan 22;130(3):60-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [High-dose chemotherapy with autologous bone marrow transplantation: 11 years' experience in Zurich].
  • [Transliterated title] Hochdosis-Chemotherapie mit autologer Stammzelltransplantation: 11 Jahre Zürcher Erfahrung.
  • High-dose chemotherapy with autologous bone marrow or peripheral blood stem cell transplantation has gained widespread acceptance for the treatment of certain malignancies.
  • Since the introduction of this therapy in 1988 we have treated 272 patients.
  • Indications for high-dose chemotherapy were high-risk large cell lymphoma and lymphoblastic or Burkitt lymphoma in first remission (73 patients), non-Hodgkin's lymphoma in chemosensitive relapse (65 patients), Hodgkin's lymphoma in relapse (52 patients), germ cell tumours with inadequate response to chemotherapy (34 patients), multiple myeloma (29 patients), and other malignancies (19 patients).
  • Treatment mortality was 1.8%.
  • High-dose chemotherapy with autologous stem cell transplantation has become a safe procedure and is considered the treatment of choice for relapsed large cell lymphoma, relapsed Hodgkin's disease, stage II or III multiple myeloma, and germ cell tumours with inadequate response to cisplatin-based chemotherapy.
  • In other situations, including aggressive lymphoma with risk factors, acute leucaemia or breast cancer, the superiority of high-dose over conventional chemotherapy remains to be proven.
  • Patients with such diseases should not receive high-dose chemotherapy outside a controlled clinical study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow Transplantation. Hematopoietic Stem Cell Transplantation. Lymphoma / therapy. Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Male. Middle Aged. Retrospective Studies. Survival Rate. Switzerland. Time Factors. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Bone Marrow Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10683881.001).
  • [ISSN] 0036-7672
  • [Journal-full-title] Schweizerische medizinische Wochenschrift
  • [ISO-abbreviation] Schweiz Med Wochenschr
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] SWITZERLAND
  •  go-up   go-down


66. Jillella AP, Kallab AM, Kutlar A: Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options. Bone Marrow Transplant; 2000 Oct;26(8):925-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autoimmune thrombocytopenia following autologous hematopoietic cell transplantation: review of literature and treatment options.
  • Autoimmune thrombocytopenia after high-dose chemotherapy and autologous bone marrow/peripheral blood stem cell transplantation occurs infrequently and only six cases meeting the criteria have been reported in the literature.
  • All six of these patients had either acute myelogenous leukemia (AML) or lymphoblastic lymphoma (LBL).
  • We report the first case of autoimmune thrombocytopenia after high-dose chemotherapy and peripheral blood stem cell transplantation in a patient with breast cancer.
  • A review of the literature has been conducted and treatment options are discussed.
  • In two patients the condition resolved with treatment and in a third patient it improved.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Purpura, Thrombocytopenic, Idiopathic / etiology
  • [MeSH-minor] Breast Neoplasms / therapy. Female. Humans. Middle Aged. Transplantation, Autologous

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11081398.001).
  • [ISSN] 0268-3369
  • [Journal-full-title] Bone marrow transplantation
  • [ISO-abbreviation] Bone Marrow Transplant.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] ENGLAND
  • [Number-of-references] 9
  •  go-up   go-down


67. Won SC, Han JW, Kwon SY, Shin HY, Ahn HS, Hwang TJ, Yang WI, Lyu CJ: Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology. Ann Hematol; 2006 Nov;85(11):787-94
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous peripheral blood stem cell transplantation in children with non-Hodgkin's lymphoma: A report from the Korean society of pediatric hematology-oncology.
  • Recent development of stratified chemotherapeutic regimens has rapidly improved the survival rate of non-Hodgkin's lymphoma (NHL) of childhood.
  • We explored the use of high-dose chemotherapy followed by autologous peripheral blood stem cell transplantation (HDC/PBSCT) for children with either refractory or recurrent NHL, and we evaluated various factors influencing outcome of HDC/PBSCT.
  • Sex, stage at diagnosis, histologic subtype (lymphoblastic, Burkitt's, and large-cell lymphoma), LDH level at diagnosis, disease status at transplantation, and preparative regimens for HDC/PBSCT were explored.
  • In regard to the patients, six had Burkitt's lymphoma, 13 had lymphoblastic lymphoma, and 14 had large-cell lymphoma.
  • The EFS for Burkitt's, lymphoblastic, and large-cell lymphoma was 66.7+/-27.2, 50.5+/-14.8, and 82.1+/-11.7%, respectively.
  • In comparison with lymphoblastic and non-lymphoblastic lymphoma, the relative risk for lymphoblastic lymphoma was higher than the others (P = 0.037).
  • EFS between anaplastic large-cell and diffuse large-cell lymphoma was 100 and 55.6+/-24.9%, respectively (P = 0.106).
  • Status at transplantation was the most predictive factor for the survival after HDC/PBSCT (EFS for CR 70.8+/-9.5% vs non-CR 20.0+/-17.9%, P = 0.008).
  • HDC/PBSCT is considered applicable to recurrent or refractory pediatric NHL patients safely and it could replace conventional chemotherapy.
  • In this study, children with CR status at the time of HDC/PBSCT showed higher survival rate.
  • However, refractory or recurrent lymphoblastic lymphoma patients showed dismal results.
  • Therefore, new therapeutic modalities may be needed for this group of NHL patients.
  • [MeSH-major] Lymphoma, Non-Hodgkin / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Humans. Infant. Korea. Male. Retrospective Studies. Salvage Therapy. Survival. Survival Analysis. Transplantation, Autologous. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Ann Hematol. 2007 Apr;86(4):309
  • (PMID = 16932891.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


68. Zhen ZJ, Xia Y, Ling JY, Tong GL, Lin L, Cai Y, Sun XF: [Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection]. Ai Zheng; 2009 Jul;28(7):718-24
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prophylaxis and treatment of modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents accompanied with infection].
  • BACKGROUND AND OBJECTIVE: Modified BFM-90 regimen has significantly improved the outcome of lymphoblastic lymphoma in children and adolescents.
  • Infection is the main side effect of this regimen, which may affect the treatment efficacy and prognosis without proper intervention.
  • METHODS: The infection rate, site, pathogen were reviewed for the infections of 104 children and adolescents suffering from lymphoblastic lymphoma at different phases of the modified BFM-90 regimen.
  • The relationship between chemotherapy, bone marrow suppression and infection was analyzed.
  • The value of procalcitonin (PCT) in identifying the infection type and the outcome of anti-infection treatment was evaluated.
  • The infection rate in consolidation chemotherapy for patients with low to intermediate risk and high risk were 17.2% and 100%, respectively.
  • The sensitivity and specificity of PCT in diagnosing sepsis were 83.3% and 70.2%, but it failed to identify the infection type.
  • After the anti-infection treatment, 296 cases were cured, four cases gave up further treatment due to financial difficulties, two cases died of sepsis.
  • CONCLUSIONS: Infections caused by modified BFM-90 regimen for lymphoblastic lymphoma in children and adolescents are closely correlated to bone marrow suppression.
  • The positive diagnosis rate of the pathogen is too low to identify most of the infection type.
  • The treatment still mainly depends on experience.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bacterial Infections / drug therapy. Cross Infection / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Respiratory Tract Infections / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / therapeutic use. Adolescent. Anti-Bacterial Agents / therapeutic use. Antifungal Agents / therapeutic use. Asparaginase / therapeutic use. Cephalosporins / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Cytarabine / therapeutic use. Daunorubicin / therapeutic use. Disease Progression. Female. Humans. Itraconazole / therapeutic use. Male. Methotrexate / therapeutic use. Mouth Diseases / drug therapy. Mouth Diseases / microbiology. Mycoses / drug therapy. Prednisone / therapeutic use. Recurrence. Remission Induction. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Bacterial Infections.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • Hazardous Substances Data Bank. Itraconazole .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19624898.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antifungal Agents; 0 / Cephalosporins; 04079A1RDZ / Cytarabine; 304NUG5GF4 / Itraconazole; 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


69. Mora J, Filippa DA, Qin J, Wollner N: Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center. Cancer; 2003 Sep 15;98(6):1283-91
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol: the 30-year experience at Memorial-Sloan-Kettering Cancer Center.
  • BACKGROUND: Until the 1970s, diffuse lymphoblastic lymphoma (DLBL) was considered incurable.
  • In the current study, the authors present what to their knowledge is the longest follow-up presented to date (median, 20 years for survivors) of the largest group of DLBL patients treated with a single protocol at a single institution.
  • Radiation therapy initially was administered to all patients with bulky disease in the primary tumor site.
  • Until 1977, the dose of radiation was 20-55 grays (Gy); from 1977 to 1989, the dose was 20 Gy.
  • After the fifth year of completion of treatment, all patients were evaluated comprehensively every 2 years.
  • RESULTS: The overall survival (OS) of the patients was 79% with a median follow-up of 20 years.
  • Seventeen patients developed a disease recurrence and 15 died of disease.
  • Six patients developed secondary malignancies, four of whom died.
  • Chemotherapy alone appears to be sufficient prophylaxis against disease recurrence in the central nervous system.
  • No disease-related or treatment-related deaths were reported to occur > 4.5 years after diagnosis in the current study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cyclophosphamide / therapeutic use. Daunorubicin / therapeutic use. Methotrexate / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Prednisone / therapeutic use. Vincristine / therapeutic use
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Disease-Free Survival. Female. Follow-Up Studies. Humans. Lymphoma, Non-Hodgkin / drug therapy. Male. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Childhood Cancer.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Steroids.
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2003 American Cancer Society.DOI 10.1002/cncr.11615
  • (PMID = 12973853.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; LSA2-L2 protocol
  •  go-up   go-down


70. Abla O, Naqvi A, Ye C, Bhattacharjee R, Shago M, Abdelhaleem M, Weitzman S: Leptomeningeal precursor B-cell lymphoblastic lymphoma in a child with minimal bone marrow involvement. J Pediatr Hematol Oncol; 2004 Jul;26(7):469-72
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Leptomeningeal precursor B-cell lymphoblastic lymphoma in a child with minimal bone marrow involvement.
  • The authors report an unusual presentation of a leptomeningeal lymphoblastic lymphoma in a 6-year-old boy with headache and papilledema as the only initial manifestations.
  • The diagnosis was confirmed by the presence of precursor B-cell lymphoblasts in the cerebrospinal fluid, with no cerebral mass and with only 9% phenotypically identical blasts in the bone marrow.
  • This patient was treated on a high-risk ALL protocol with intensive systemic/intrathecal chemotherapy plus cranial irradiation, and he remained in complete remission 6 months after his initial diagnosis.
  • [MeSH-major] Bone Marrow / pathology. Leukemic Infiltration / pathology. Lymphoma, B-Cell / pathology. Meninges / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15218426.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


71. Mai W, Meng H, Jin J, Wang L: Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma. Eur J Haematol; 2006 Nov;77(5):445-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment with bortezomib in a patient with heavily pretreated refractory T-cell lymphoblastic lymphoma.
  • T-cell lymphoblastic lymphomas are highly aggressive non-Hodgkin's lymphoma (NHL) and account for approximately 3% of all adult NHL histologies, with poor prognosis.
  • We describe a 38-year-old patient with T-cell lymphoblastic lymphoma, who responds to bortezomib and doxorubincin combination, following a failure of conventional chemotherapy.
  • Two months after treatment, the patient showed near complete remission of the lymphadenopathy.
  • To our knowledge, this is the first case of T-cell lymphoblastic lymphoma treated with bortezomib.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Boronic Acids / administration & dosage. Lymphoma, T-Cell / drug therapy. Pyrazines / administration & dosage
  • [MeSH-minor] Adult. Bortezomib. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Synergism. Humans. Male. Remission Induction

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. BORTEZOMIB .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16930138.001).
  • [ISSN] 0902-4441
  • [Journal-full-title] European journal of haematology
  • [ISO-abbreviation] Eur. J. Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Pyrazines; 69G8BD63PP / Bortezomib; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin
  •  go-up   go-down


72. Sun XF, Xia ZJ, Zhen ZJ, Xiang XJ, Xia Y, Ling JY, Liu DG, Huang HQ, Zhen L, Luo WB, Lin H, Guan ZZ: Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma. Int J Clin Oncol; 2008 Oct;13(5):436-41
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensive chemotherapy improved treatment outcome for Chinese children and adolescents with lymphoblastic lymphoma.
  • BACKGROUND: Lymphoblastic lymphoma (LBL) is a highly aggressive lymphoma, for which intensive chemotherapy is necessary.
  • This study was designed to evaluate the efficacy and toxicity of a modified acute lymphoblastic leukemia (ALL)-Berlin-Frankfurt-Münster (BFM)-90-based protocol in Chinese children and adolescents with LBL.
  • Forty-eight (80%) patients had T-cell LBL, and 59 (98.3%) of the patients were stage III/IV.
  • At the end of induction remission Ia (day 33), 3 patients had died of treatment-related toxicity.
  • At a median follow-up of 35 months, event-free survival was 78.81%+/-0.05 for all patients; the figure was 88.34%+/-0.05 for the moderate-risk group (90.91%+/-0.08 for stage III, 87.68%+/-0.06 for stage IV, 100% for those with B-cell LBL, 84.78%+/-0.06 for those with T-cell LBL, and 82.94%+/-0.08 for stage IV patients with more than 25% blast cells in bone marrow [BM]).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Administration Schedule. Humans. Injections, Spinal. Leucovorin / administration & dosage. Methotrexate / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Leuk Lymphoma. 1999 Dec;36(1-2):101-8 [10613454.001]
  • [Cites] Leukemia. 2002 Jun;16(6):1099-111 [12040440.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Br J Haematol. 2004 Jan;124(1):33-46 [14675406.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] Semin Oncol. 1980 Sep;7(3):332-9 [7414342.001]
  • [Cites] Pediatr Blood Cancer. 2004 Jan;42(1):24-9 [14752790.001]
  • [Cites] Blood. 2000 Jun 1;95(11):3310-22 [10828010.001]
  • (PMID = 18946754.001).
  • [ISSN] 1341-9625
  • [Journal-full-title] International journal of clinical oncology
  • [ISO-abbreviation] Int. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


73. Qin Y, Shi YK, He XH, Yang JL, Yang S, Yu YX, Li B, Wang QL, Zhou LQ, Sun Y: [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil]. Ai Zheng; 2006 Apr;25(4):481-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical features of 89 patients with primary non-Hodgkin's lymphoma of the tonsil].
  • BACKGROUND & OBJECTIVE: Head and neck lymphoma develops predominantly in the tonsil.
  • This study was to investigate the clinical features of primary non-Hodgkin's lymphoma (NHL) of the tonsil, and to explore possible ways to improve the prognosis and quality of life of the patients after treatment.
  • METHODS: Clinical data of 89 naive patients with NHL of the tonsil, treated from May 1990 to Jan.
  • Stage I-II patients received radiochemotherapy-predominant treatment, whereas stage III-IV patients received chemotherapy-predominant treatment.
  • RESULTS: Of the 89 cases, 60 (67%) were diffuse large B-cell subtype, 11 (12%) were peripheral T-cell subtype, 5 (6%) were indolent lymphoma, 1 was anaplastic large T-cell lymphoma, and 1 was T lymphoblastic lymphoma; 81 (91%) were stage I-II disease.
  • Of the 89 patients, 58 (72%) received radiochemotherapy, 19 (21%) received radiotherapy alone, 3 received chemotherapy alone, and 1 received radiochemotherapy combined with rituximab.
  • Diffuse large B-cell lymphoma is the most common pathologic subtype.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin. Tonsillar Neoplasms
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Combined Modality Therapy. Cyclophosphamide / therapeutic use. Disease-Free Survival. Doxorubicin / therapeutic use. Drug Resistance, Neoplasm. Female. Follow-Up Studies. Humans. Lymphoma, Large B-Cell, Diffuse / drug therapy. Lymphoma, Large B-Cell, Diffuse / pathology. Lymphoma, Large B-Cell, Diffuse / radiotherapy. Lymphoma, T-Cell, Peripheral / drug therapy. Lymphoma, T-Cell, Peripheral / pathology. Lymphoma, T-Cell, Peripheral / radiotherapy. Male. Middle Aged. Neoplasm Recurrence, Local. Neoplasm Staging. Prednisone / therapeutic use. Quality of Life. Retrospective Studies. Survival Rate. Vincristine / therapeutic use. Young Adult

  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613685.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


74. Banklau C, Jindadamrongwech S, Sawangpanich R, Apibal S, Hongeng S, Paisooksantivatana K, Pakakasama S: Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia. Hematol Oncol Stem Cell Ther; 2010;3(3):103-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of genetic alterations of cytarabine- metabolizing enzymes in childhood acute lymphoblastic leukemia.
  • Currently, treatment of childhood acute lymphoblastic leukemia (ALL) includes cytarabine, especially in high-risk patients.
  • Therefore, we hypothesized that a genetic variation of dCK and CDA genes may influence the risk of cytarabine-related toxicities and early response to treatment.
  • PATIENTS AND METHODS: We included children diagnosed with ALL and lymphoblastic lymphoma (LL) stage III and IV.
  • The patients received a modified St Jude Total Therapy Study XV protocol.
  • RESULTS: Ninety-four children with ALL (n=90) and LL (n=4) were analyzed.
  • The median age at diagnosis was 5.8 years (range, 0.4-15 years).
  • All four SNPs showed predominant wild type alleles.
  • CONCLUSION: The dCK-360G allele was found to increase the risk of mucositis after exposure to low-dose cytarabine in childhood ALL therapy.
  • [MeSH-major] Cytarabine / therapeutic use. Cytidine Deaminase / genetics. Deoxycytidine Kinase / genetics. Polymorphism, Single Nucleotide. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / genetics
  • [MeSH-minor] Adolescent. Alleles. Antigens, CD19 / metabolism. Antigens, CD45 / metabolism. Antimetabolites, Antineoplastic / adverse effects. Antimetabolites, Antineoplastic / metabolism. Antimetabolites, Antineoplastic / therapeutic use. Child. Child, Preschool. Dose-Response Relationship, Drug. Female. Flow Cytometry. Gene Frequency. Genotype. Humans. Infant. Male. Mucositis / chemically induced. Neoplasm Staging. Neoplasm, Residual / diagnosis. Neoplasm, Residual / genetics. Neoplasm, Residual / metabolism. Thrombocytopenia / chemically induced. Treatment Outcome

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia, Childhood.
  • Hazardous Substances Data Bank. CYTARABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20890066.001).
  • [ISSN] 1658-3876
  • [Journal-full-title] Hematology/oncology and stem cell therapy
  • [ISO-abbreviation] Hematol Oncol Stem Cell Ther
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Saudi Arabia
  • [Chemical-registry-number] 0 / Antigens, CD19; 0 / Antimetabolites, Antineoplastic; 04079A1RDZ / Cytarabine; EC 2.7.1.74 / Deoxycytidine Kinase; EC 3.1.3.48 / Antigens, CD45; EC 3.5.4.5 / Cytidine Deaminase
  •  go-up   go-down


75. Okada A, Hatori M, Hosaka M, Watanuki M, Itoi E: Secondary osteosarcoma arising after treatment for childhood hematologic malignancies. Ups J Med Sci; 2009;114(4):249-55
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Secondary osteosarcoma arising after treatment for childhood hematologic malignancies.
  • Secondary osteosarcoma arising after the treatment of hematologic malignancies other than Hodgkin's lymphoma is rare.
  • We report two cases of secondary osteosarcoma arising after treatment for childhood hematologic malignancies (non-Hodgkin's lymphoma and lymphoblastic leukemia).
  • A 10-year-old boy, at the age of 3, was diagnosed with non-Hodgkin's lymphoma.
  • He received chemotherapy, radiation, and bone-marrow transplantation and then was in complete remission.
  • A 26-year-old man, at the age of 6, was diagnosed as having acute lymphoblastic leukemia (ALL).
  • He received chemotherapy, radiation, and peripheral blood stem cell transplantation (PBSCT).
  • We should rule out secondary osteosarcoma at the abnormal elevation of ALP during clinical follow-up of patients after treatment of childhood hematologic malignancies.
  • [MeSH-major] Bone Neoplasms / etiology. Hematologic Neoplasms / therapy. Neoplasms, Second Primary / etiology. Osteosarcoma / etiology
  • [MeSH-minor] Adult. Alkaline Phosphatase / blood. Biomarkers, Tumor / blood. Child. Humans. Lymphoma, T-Cell / therapy. Male. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy

  • Genetic Alliance. consumer health - Osteosarcoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Bone Joint Surg Am. 1972 Oct;54(7):1479-89 [4510800.001]
  • [Cites] Eur J Surg Oncol. 2009 Oct;35(10):1030-6 [19232880.001]
  • [Cites] Skeletal Radiol. 1982;8(4):279-83 [6293097.001]
  • [Cites] J Clin Pathol. 1987 Apr;40(4):398-403 [3584482.001]
  • [Cites] N Engl J Med. 1987 Sep 3;317(10):588-93 [3475572.001]
  • [Cites] Tumori. 1987 Aug 31;73(4):331-6 [3477902.001]
  • [Cites] Br J Cancer. 1987 Sep;56(3):339-47 [2822073.001]
  • [Cites] Cancer. 1991 Jan 1;67(1):193-201 [1985716.001]
  • [Cites] Oncology (Williston Park). 1991 May;5(5):135-41; discussion 142, 147-8 [1831995.001]
  • [Cites] N Engl J Med. 1991 Nov 7;325(19):1330-6 [1922234.001]
  • [Cites] Clin Orthop Relat Res. 1992 Jan;(274):275-81 [1729013.001]
  • [Cites] Blood. 2000 May 1;95(9):2770-5 [10779419.001]
  • [Cites] Eur J Radiol. 2001 Jun;38(3):235-48 [11399379.001]
  • [Cites] Eur J Cancer. 2001 Nov;37(16):2074-9; discussion 2079-81 [11597387.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1959-66 [11745271.001]
  • [Cites] J Pediatr Hematol Oncol. 2002 Oct;24(7):572-4 [12368699.001]
  • [Cites] Int J Clin Oncol. 2002 Oct;7(5):318-21 [12402067.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(5):353-9 [12634726.001]
  • [Cites] Acta Paediatr Scand. 1991 Dec;80(12):1220-8 [1785295.001]
  • [Cites] Clin Chim Acta. 1991 Sep 14;201(1-2):27-33 [1790624.001]
  • [Cites] J Bone Joint Surg Am. 1992 Aug;74(7):1079-83 [1522094.001]
  • [Cites] Cancer. 1993 Feb 15;71(4):1224-30 [8435797.001]
  • [Cites] Ann Clin Biochem. 1993 Jul;30 ( Pt 4):355-72 [8379650.001]
  • [Cites] BMJ. 1993 Oct 23;307(6911):1030-6 [8251777.001]
  • [Cites] Oncology. 1996 Jul-Aug;53(4):275-80 [8692530.001]
  • [Cites] Cancer. 1998 Jan 1;82(1):8-34 [9428476.001]
  • [Cites] Int J Cancer. 1998 Jul 29;77(3):370-7 [9663598.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Nov 15;63(4):1169-74 [16054775.001]
  • [Cites] Cancer. 1979 Jun;43(6):2178-81 [287547.001]
  • (PMID = 19961270.001).
  • [ISSN] 2000-1967
  • [Journal-full-title] Upsala journal of medical sciences
  • [ISO-abbreviation] Ups. J. Med. Sci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 3.1.3.1 / Alkaline Phosphatase
  • [Other-IDs] NLM/ PMC2852780
  •  go-up   go-down


76. Abromowitch M, Sposto R, Perkins S, Zwick D, Siegel S, Finlay J, Cairo MS, Children's Oncology Group: Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group. Br J Haematol; 2008 Oct;143(2):261-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Shortened intensified multi-agent chemotherapy and non-cross resistant maintenance therapy for advanced lymphoblastic lymphoma in children and adolescents: report from the Children's Oncology Group.
  • Pediatric lymphoblastic lymphoma (LL) has utilized treatment strategies similar to childhood acute lymphoblastic leukaemia (ALL) with prolonged maintenance chemotherapy.
  • We report the results of a pilot study to estimate the feasibility, toxicity and efficacy of a 12-month aggressive multi-agent chemotherapy regimen in children and adolescents with advanced LL.
  • Between July 1994 and June 1997, 85 eligible children and adolescents with advanced LL (Stage III/IV) were enrolled on this pilot study.
  • Patients achieving a complete response following induction and consolidation received six cycles of maintenance chemotherapy for a total duration of 12 months.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):416-21 [10627444.001]
  • [Cites] Eur J Cancer. 2008 Apr;44(6):840-6 [18342502.001]
  • [Cites] Semin Hematol. 2003 Oct;40(4):274-80 [14582078.001]
  • [Cites] N Engl J Med. 1983 Mar 10;308(10):559-65 [6338381.001]
  • [Cites] J Clin Oncol. 1983 Sep;1(9):537-41 [6689428.001]
  • [Cites] Br J Cancer. 1984 Oct;50(4):457-62 [6333247.001]
  • [Cites] Blood. 1985 Nov;66(5):1110-4 [3840395.001]
  • [Cites] J Clin Oncol. 1986 May;4(5):744-52 [3517244.001]
  • [Cites] Med Pediatr Oncol. 1992;20(2):105-13 [1734214.001]
  • [Cites] Br J Haematol. 1992 Oct;82(2):310-6 [1419812.001]
  • [Cites] J Clin Oncol. 1993 Jun;11(6):1024-32 [8501488.001]
  • [Cites] J Clin Oncol. 1995 Jun;13(6):1368-76 [7751881.001]
  • [Cites] Pediatr Blood Cancer. 2005 Nov;45(6):753-69 [15929129.001]
  • [Cites] J Clin Oncol. 2006 Jan 20;24(3):491-9 [16421426.001]
  • [Cites] Pediatr Blood Cancer. 2006 Aug;47(2):130-40 [16358311.001]
  • [Cites] Cancer. 2003 Sep 15;98(6):1283-91 [12973853.001]
  • (PMID = 18759768.001).
  • [ISSN] 1365-2141
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098543; None / None / / U10 CA098543-08; United States / NCI NIH HHS / CA / CA98543; United States / NCI NIH HHS / CA / U10 CA098543-08
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS107033; NLM/ PMC3057023
  •  go-up   go-down


77. Williams LE, Pruitt AF, Thrall DE: Chemotherapy followed by abdominal cavity irradiation for feline lymphoblastic lymphoma. Vet Radiol Ultrasound; 2010 Nov-Dec;51(6):681-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy followed by abdominal cavity irradiation for feline lymphoblastic lymphoma.
  • Combination chemotherapy is standard care for feline lymphoma, although clinically relevant improvements in remission duration are unlikely to result from manipulations of chemotherapy agents alone.
  • Lymphopoietic tissues generally are sensitive to radiation, and support for chemoradiotherapy as a treatment for lymphoma is found in both humans and dogs.
  • The goal of this prospective pilot study was to determine the normal tissue tolerance to 15 Gy total abdomen fractionated radiation therapy following induction chemotherapy in cats with lymphoblastic lymphoma.
  • Eight cats with lymphoblastic gastrointestinal or multicentric lymphoma confined to the abdominal cavity were treated with a 6-week combination chemotherapy protocol followed 2 weeks later by whole-abdomen radiation therapy consisting of 10 daily fractions of 1.5 Gy.
  • Treatment was well tolerated; renal insufficiency documented in one cat at the start of radiation therapy progressed to stable chronic renal failure.
  • One cat not in complete remission at the time of radiation therapy relapsed 2 weeks later, one cat with multicentric lymphoma relapsed with hepatic large granular lymphoma, and one cat was euthanatized 3 weeks following completion of radiation therapy for other reasons; no evidence of lymphoma or radiation toxicoses was identified on post mortem evaluation.
  • The remaining five cats remain in remission at least 266 days after starting therapy; median remission duration has not been reached (range, > 266 to > 1332 days).
  • Results of this study suggest that 15 Gy total abdomen fractionated radiation therapy after induction chemotherapy is tolerated satisfactorily.
  • [MeSH-major] Abdominal Neoplasms / veterinary. Cat Diseases / radiotherapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / veterinary
  • [MeSH-minor] Animals. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Cats. Combined Modality Therapy / veterinary. Pilot Projects. Radiotherapy Dosage. Remission Induction / methods. Treatment Outcome

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21158247.001).
  • [ISSN] 1058-8183
  • [Journal-full-title] Veterinary radiology & ultrasound : the official journal of the American College of Veterinary Radiology and the International Veterinary Radiology Association
  • [ISO-abbreviation] Vet Radiol Ultrasound
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


78. Butrón Valdez K, Ramírez Galves M, Germes Piña F, Ramos Martínez E, Zamora Perea A: [Systemic lymphoma cells with T precursor condition of extreme female genital tract. A case report and literature review]. Ginecol Obstet Mex; 2009 Jun;77(6):291-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Systemic lymphoma cells with T precursor condition of extreme female genital tract. A case report and literature review].
  • [Transliterated title] Linfoma linfoblástico sistémico de células precursoras T con afección extrema del aparato genital femenino. Reporte de un caso y revisión de la bibliografía.
  • Primary female genital tract non Hodgkin's lymphoma is a rare presentation for a common disease in the childhood, and its classification as primary extranodal lymphoma is still controversial.
  • There are a few cases reported as a primary precursor B-cell lymphoblastic lymphoma of the female genital tract, but there is not any case reported as primary precursor T-cell lymphoblastic lymphoma of the ovary in childhood.
  • The chemotherapy regimen comprised of CHOP (Cyclophosphamide, Hydroxydaunorubicin, Oncovin, Prednisone/Prednisolone) and methotrexate, 3 months later presents left facial hemiparesia follow by right facial hemiparesia, 7 months later presents more Central Nervous System (CNS) complications and apparently was complicated with acute lymphocitic leukemia and after 16 months from the diagnosis, following by a torpid evolution, the pacient finally died.
  • [MeSH-major] Genital Neoplasms, Female. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19681371.001).
  • [ISSN] 0300-9041
  • [Journal-full-title] Ginecología y obstetricia de México
  • [ISO-abbreviation] Ginecol Obstet Mex
  • [Language] spa
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] Mexico
  • [Number-of-references] 19
  •  go-up   go-down


79. McMillan A: Central nervous system-directed preventative therapy in adults with lymphoma. Br J Haematol; 2005 Oct;131(1):13-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Central nervous system-directed preventative therapy in adults with lymphoma.
  • All adult patients with Burkitt lymphoma or lymphoblastic lymphoma should receive central nervous system (CNS)-directed therapy with both intrathecal and high-dose systemic chemotherapy.
  • There is no evidence to support the routine use of prophylactic CNS-directed therapy in any specific subgroup of adult patients with 'low grade' lymphomas.
  • There are some anatomical sites where involvement by lymphoma is associated with a higher risk of CNS relapse.
  • There is evidence of good efficacy when intrathecal chemotherapy and high-dose systemic chemotherapy are used in combination.
  • It is not clear how the best balance between the 'sensitivity' and 'specificity' of the choice of patients to receive CNS-directed therapy can be achieved.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Central Nervous System Neoplasms / prevention & control. Lymphoma / prevention & control
  • [MeSH-minor] Aged. Biomarkers, Tumor / blood. Burkitt Lymphoma / blood. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / prevention & control. Female. Humans. Injections, Spinal. L-Lactate Dehydrogenase / blood. Male. Middle Aged. Precursor Cell Lymphoblastic Leukemia-Lymphoma / blood. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / prevention & control. Prognosis. Recurrence. Risk Assessment

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16173958.001).
  • [ISSN] 0007-1048
  • [Journal-full-title] British journal of haematology
  • [ISO-abbreviation] Br. J. Haematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; EC 1.1.1.27 / L-Lactate Dehydrogenase
  • [Number-of-references] 47
  •  go-up   go-down


80. Blayney DW, LeBlanc ML, Grogan T, Gaynor ER, Chapman RA, Spiridonidis CH, Taylor SA, Bearman SI, Miller TP, Fisher RI, Southwest Oncology Group: Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol; 2003 Jul 1;21(13):2466-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349).
  • PURPOSE: To test the hypothesis that therapy of intermediate- and high-grade (excluding Burkitt lymphoblastic) lymphoma with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) could be safely dose-intensified with routine filgrastim support.
  • PATIENTS AND METHODS: Eligible patients were those who were previously untreated and who had either bulky stage II, or stage III or IV lymphoma with working formulation histology D, E, F, G, H, or J; performance status < or = 2; and acceptable end organ function.
  • Therapy was dose-intensified CHOP (CHOP-DI) with filgrastim support.
  • Three fatal treatment-related events occurred.
  • CONCLUSION: Treatment with CHOP-DI can be safely administered in the cooperative group setting and results in improved survival.
  • CHOP-DI, given every 2 weeks at escalated doses, is a strategy that should be tested in a future randomized clinical trial in lymphoma.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, Non-Hodgkin / drug therapy
  • [MeSH-minor] Adult. Aged. Cyclophosphamide / administration & dosage. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Female. Granulocyte Colony-Stimulating Factor / administration & dosage. Humans. Infusions, Intravenous. Injections, Subcutaneous. Male. Middle Aged. Neoplasm Staging. Prednisone / administration & dosage. Vincristine / administration & dosage

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Oncol. 2003 Jul 1;21(13):2457-9 [12829662.001]
  • (PMID = 12829664.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA04919; United States / NCI NIH HHS / CA / CA04920; United States / NCI NIH HHS / CA / CA11083; United States / NCI NIH HHS / CA / CA12213; United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA13612; United States / NCI NIH HHS / CA / CA14028; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA22433; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35119; United States / NCI NIH HHS / CA / CA35128; United States / NCI NIH HHS / CA / CA35176; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35192; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA35262; United States / NCI NIH HHS / CA / CA35281; United States / NCI NIH HHS / CA / CA35431; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA45377; United States / NCI NIH HHS / CA / CA45450; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45807; United States / NCI NIH HHS / CA / CA46136; United States / NCI NIH HHS / CA / CA46282; United States / NCI NIH HHS / CA / CA46441; United States / NCI NIH HHS / CA / CA52386; United States / NCI NIH HHS / CA / CA52654; United States / NCI NIH HHS / CA / CA58416; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA63844; United States / NCI NIH HHS / CA / CA63845; United States / NCI NIH HHS / CA / CA63850; United States / NCI NIH HHS / CA / CA74647; United States / NCI NIH HHS / CA / CA76462; United States / NCI NIH HHS / CA / CA96429
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 143011-72-7 / Granulocyte Colony-Stimulating Factor; 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


81. Kisor DF: Nelarabine use in leukemias. Drugs Today (Barc); 2006 Jul;42(7):455-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Drug discovery and development over the past 60 years has played a central role in the continuous improvement in survival rates of patients undergoing treatment for acute lymphoblastic leukemia.
  • It has recently been suggested that in children and adolescents diagnosed with acute lymphoblastic leukemia, an overall cure rate of 90% may be achieved (1, 2).
  • Cure rates in adults, typically less than 40%, are considerably lower than in the younger populations, even in the face of currently prescribed optimal drug therapy and supportive care (3-5).
  • The search for more effective and safer anti-leukemia therapy continues to identify agents and combinations of agents that have activity against specific types of acute lymphoblastic leukemia (1).
  • This review presents a new compound, nelarabine, that has shown efficacy in treating patients with T-cell acute lymphoblastic leukemia or T-cell lymphoblastic lymphoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Arabinonucleosides / therapeutic use. Leukemia-Lymphoma, Adult T-Cell / drug therapy
  • [MeSH-minor] Humans. Molecular Structure. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2006 Prous Science. All rights reserved.
  • (PMID = 16894400.001).
  • [ISSN] 1699-3993
  • [Journal-full-title] Drugs of today (Barcelona, Spain : 1998)
  • [ISO-abbreviation] Drugs Today
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Spain
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Arabinonucleosides; 60158CV180 / nelarabine
  • [Number-of-references] 38
  •  go-up   go-down


82. Millot F, Suciu S, Philippe N, Benoit Y, Mazingue F, Uyttebroeck A, Lutz P, Mechinaud F, Robert A, Boutard P, Marguerite G, Ferster A, Plouvier E, Rialland X, Behard C, Plantaz D, Dresse MF, Philippet P, Norton L, Thyss A, Dastugue N, Waterkeyn C, Vilmer E, Otten J, Children's Leukemia Cooperative Group of the European Organiztaion for Research and Treatment of Cancer: Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial. J Clin Oncol; 2001 Apr 01;19(7):1935-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Value of high-dose cytarabine during interval therapy of a Berlin-Frankfurt-Munster-based protocol in increased-risk children with acute lymphoblastic leukemia and lymphoblastic lymphoma: results of the European Organization for Research and Treatment of Cancer 58881 randomized phase III trial.
  • PURPOSE: The European Organization for Research and Treatment of Cancer 58881 study was designed to test in a prospective multicentric randomized trial the value of high-dose (HD) intravenous (IV) cytarabine (Ara-C) added to HD IV methotrexate (MTX) to reduce the incidence of CNS and systemic relapses in children with increased-risk acute lymphoblastic leukemia (ALL) or stage III and IV lymphoblastic lymphoma treated with a Berlin-Frankfurt-Munster (BFM)-based regimen.
  • PATIENTS AND METHODS: After completion of induction-consolidation phase, children with increased-risk (risk factor > 0.8 or T-lineage) ALL or stage III and IV lymphoblastic lymphoma were randomized to receive four courses of HD MTX (5 g/m(2) over 24 hours every 2 weeks) and four intrathecal administrations of MTX (Arm A) or the same treatment schedule with additional HD IV Ara-C (1 g/m(2) in bolus injection 12 and 24 hours after the start of each MTX infusion) (Arm B).
  • RESULTS: Between January 1990 and January 1996, 653 patients with ALL (593 patients) or lymphoblastic lymphoma (60 patients) were randomized: 323 were assigned to Arm A (without Ara-C) and 330 to Arm B (with Ara-C).
  • The estimated 6-year disease-free survival (DFS) rate was similar (log-rank P =.67) in the two treatment groups: 70.4% (SE = 2.6%) in Arm A and 71.0% (SE = 2.5%) in Arm B.
  • The 6-year DFS rate was similar for ALL and LL patients: 70.2% (SE = 1.9%) versus 76.3% (SE = 5.6%).
  • CONCLUSION: Prevention of CNS relapse was satisfactorily achieved with HD IV MTX and intrathecal injections of MTX in children with increased-risk ALL or stage III and IV lymphoblastic lymphoma treated with our BFM-based treatment protocol in which cranial irradiation was omitted.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Cytarabine / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Actuarial Analysis. Adolescent. Asparaginase / administration & dosage. Central Nervous System / pathology. Child. Child, Preschool. Daunorubicin / administration & dosage. Disease-Free Survival. Drug Synergism. Europe / epidemiology. Female. Humans. Infant. Infant, Newborn. Infusions, Intravenous. Injections, Spinal. Leukemic Infiltration / epidemiology. Leukemic Infiltration / prevention & control. Male. Methotrexate / administration & dosage. Prednisone / administration & dosage. Regression Analysis. Risk. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • ORBi (University of Liege). Free full Text at ORBi .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11283125.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5U10-CA11488-20; United States / NCI NIH HHS / CA / 5U10-CA11488-29
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; EC 3.5.1.1 / Asparaginase; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; PVDA protocol
  •  go-up   go-down


83. Takahashi K, Goi K, Satou H, Nemoto A, Uno K, Inukai T, Sugita K, Nakazawa S: [NSE-positive lymphoblastic lymphoma in a boy with cutaneous involvement, giant splenomegaly, and hyper-gamma globulinemia]. Rinsho Ketsueki; 2004 Dec;45(12):1247-51
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [NSE-positive lymphoblastic lymphoma in a boy with cutaneous involvement, giant splenomegaly, and hyper-gamma globulinemia].
  • We report a 6-year-old boy who was diagnosed as having neuron-specific enolase (NSE)-positive pro-T cell type lymphoblastic lymphoma preceded with a variety of symptoms such as skin rash, giant splenomegaly, and hyper-gamma globulinemia.
  • However, no specific treatments were started at this point because a cervical lymph node biopsy failed to show malignancy and the patient's signs and symptoms resolved spontaneously.
  • Two months later, oral prednisolone therapy was started due to recurrence of the fever and erythema, but resulted in exacerbation of the skin lesions and generalized lymphadenopathy.
  • A biopsy of the right inguinal lymph node performed in January 2000 revealed proliferation of lymphoblastic cells positive for CD3, CD5 and NSE with a rearrangement of T cell receptor gene Jdelta, leading to the diagnosis of lymphoblastic lymphoma.
  • After intensified chemotherapy, he received an autologous peripheral blood stem cell transplantation and has been in complete remission for 4 years.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Splenomegaly.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15678916.001).
  • [ISSN] 0485-1439
  • [Journal-full-title] [Rinshō ketsueki] The Japanese journal of clinical hematology
  • [ISO-abbreviation] Rinsho Ketsueki
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] EC 4.2.1.11 / Phosphopyruvate Hydratase
  •  go-up   go-down


84. Yan Z, Yang B, Wang QS, Wang LL, Han XP, Ren F, Yu L: [Clinical pathological features of the 8p11 myeloproliferative syndrome]. Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2010 Oct;18(5):1321-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical pathological features of the 8p11 myeloproliferative syndrome].
  • This study was aimed to investigate the clinico-pathological features, diagnosis and treatment of the 8p11 (eight p11) myeloproliferative syndrome (EMS).
  • The cell immunophenotypes were analysed by flow cytometry.
  • The results indicated that EMS was a relatively rare disease characterized by the occurrence of a bcr/abl-negative myeloproliferative disorder and a T-cell lymphoblastic lymphoma (T-LBL).
  • Flow cytometric immunophenotyping showed increased myelomonoblasts; cytogenetic analysis showed a translocation at the 8p11 locus; RT-PCR demonstrated non bcr/abl fusion gene.
  • At the molecular level, all cases carried a chromosomal abnormality involving the fibroblast growth factor receptor 1 (FGFR1) at chromosome 8p11.
  • Majority of patients terminate in acute myeloid leukemia which is resistant to conventional chemotherapy.
  • Currently, the only curative option appears to be allogeneic hematopoietic stem cell transplantation.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21129285.001).
  • [ISSN] 1009-2137
  • [Journal-full-title] Zhongguo shi yan xue ye xue za zhi
  • [ISO-abbreviation] Zhongguo Shi Yan Xue Ye Xue Za Zhi
  • [Language] CHI
  • [Publication-type] Case Reports; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  •  go-up   go-down


85. Benzon HT, Iqbal M, Tallman MS, Boehlke L, Russell EJ: Superior sagittal sinus thrombosis in a patient with postdural puncture headache. Reg Anesth Pain Med; 2003 Jan-Feb;28(1):64-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CASE REPORT: A 32-year-old man with lymphoblastic lymphoma received treatment with daunorubicin, vincristine, and prednisone.
  • He developed postural headache and severe nausea and vomiting after a diagnostic lumbar puncture.
  • Patients with lymphoblastic lymphoma who had treatment with L-asparaginase and steroid are predisposed to the development of cortical venous thrombosis and may have this syndrome in addition to a dural puncture headache.
  • [MeSH-minor] Adult. Analgesics / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Blood Patch, Epidural. Humans. Leukemia-Lymphoma, Adult T-Cell / complications. Leukemia-Lymphoma, Adult T-Cell / drug therapy. Magnetic Resonance Imaging. Male

  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Headache.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12567347.001).
  • [ISSN] 1098-7339
  • [Journal-full-title] Regional anesthesia and pain medicine
  • [ISO-abbreviation] Reg Anesth Pain Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Analgesics
  •  go-up   go-down


86. Terui K, Takahashi Y, Sasaki S, Kudo K, Kamio T, Ito E: Guillain-Barré syndrome mimicking acute methotrexate-associated encephalopathy in an adolescent patient with lymphoblastic lymphoma. J Pediatr Hematol Oncol; 2010 Nov;32(8):615-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guillain-Barré syndrome mimicking acute methotrexate-associated encephalopathy in an adolescent patient with lymphoblastic lymphoma.
  • We describe an adolescent case of Guillain-Barré syndrome (GBS) mimicking acute methotrexate-associated encephalopathy during chemotherapy for lymphoblastic lymphoma.
  • After the initiation of intravenous immunoglobulin therapy her symptoms improved rapidly, and the diagnosis of GBS was confirmed by nerve conduction studies and cerebrospinal fluid examination in recovery phase.
  • GBS should be considered in the differential diagnosis of acute methotrexate-associated encephalopathy, although GBS is a rare neurologic complication.
  • [MeSH-major] Antimetabolites, Antineoplastic / administration & dosage. Brain Diseases / chemically induced. Brain Diseases / diagnosis. Guillain-Barre Syndrome / diagnosis. Methotrexate / administration & dosage. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] Adolescent. Diagnosis, Differential. Female. Humans


87. Diagne I, Diagne-Gueye NR, Gaye-Ly K, Sow D, Camara B, Diack-Mbaye A, Signate-Sy H, Ba M, Sarr M, Moreira C, Kuakuvi N: [Management problems of malignant hemopathies among children in Senegal]. Dakar Med; 2002;47(1):12-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Management problems of malignant hemopathies among children in Senegal].
  • [Transliterated title] Problèmes posés par la prise en charge des hémopathies malignes chez l'enfant au Sénégal.
  • Malignant hemopathies are not considered as public health priority in Senegal because of their infrequency in comparison with infections and malnutrition.
  • However they remain usually lethal instead of a great improvement of their prognosis in suitable therapeutic conditions.
  • During this ten years period 25 cases of malignant hemopathies were diagnosed among 32,789 hospitalised children, representing an hospital prevalence of 0.08 per cent.
  • Mean age at the desease diagnosis was 9.5 years and sex ratio 2.57 (18 boys and 7 girls).
  • The malignant type was acute leukemia (AL) in 11 cases (44%) including 9 cases of of acute lymphoblastic leukemia (ALL) and 2 cases of acute myeloblastic leukemia (AML); chronic myeloid leukemia (CML) in 2 cases (8%), Hodgkin's desease (HD) in 9 cases (36%) and non hodgkinian lymphoma (NHL) in 3 cases.
  • NHLwere Burkitt type in 2casesand lymphoblastic type in 1 case.
  • Their was no maxillary or facial localisation in Burkitt type lymphoma.
  • The mean duration between the first clinical symptomes and the diagnosis of the disease was 4 months and delayed diagnosis was mainly due to delayed transfer from peripheral health services to hospital.
  • Among 19 patients whose records were available, 17 were subjected to chemotherapy.
  • However reference protocols were completely applyed in only 2 cases, one with HD and an other with lymphoblastic lymphoma.
  • Eventually, this study showed that, in our hospital, children with malignant hemopathies did not derive benefit of therapeutic progress enregistered long time ago in developed countries, since they remain constantly lethal.
  • The main factors of lethality could be delayed transfer to hospital because of lack of knowledge about these pathologies in the peripheral health services and poor therapeutic conditions in reference hospitals.
  • Creation of specialised clinical haematology department could enable us to improve the prognosis of these affections by an optimal use of available human and material ressources.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15776584.001).
  • [ISSN] 0049-1101
  • [Journal-full-title] Dakar médical
  • [ISO-abbreviation] Dakar Med
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Senegal
  •  go-up   go-down


88. Ezenekwe AM, Collins BT, Ponder TB: Fine needle aspiration biopsy of precursor B-cell lymphoblastic lymphoma presenting as a sacral mass. A case report. Acta Cytol; 2004 Mar-Apr;48(2):239-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle aspiration biopsy of precursor B-cell lymphoblastic lymphoma presenting as a sacral mass. A case report.
  • BACKGROUND: Lymphoblastic lymphoma (LBL) is a high grade, aggressive neoplasm, usually presenting in children and young adults.
  • Precursor B-cell LBL is uncommon and may present with cutaneous or, less likely, bone lesions.
  • CASE: A 50-year-old man presented with a 3-month history of a 7 x 5 x 4-cm mass in the sacral region.
  • Diagnosis of a chordoma was radiologically favored.
  • Computed tomography (CT)-guided FNAB, with flow cytometry and cytochemical staining, was used to make the diagnosis of precursor B-cell LBL.
  • CONCLUSION: FNAB was instrumental in reaching this unusual diagnosis in a patient who was free of disease after chemotherapy.
  • [MeSH-major] Bone Neoplasms / pathology. Lymphoma, B-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Sacrum / pathology
  • [MeSH-minor] Antigens, CD / biosynthesis. B-Lymphocytes / metabolism. B-Lymphocytes / pathology. Biomarkers, Tumor / biosynthesis. Biopsy, Fine-Needle. Chordoma / pathology. Diagnosis, Differential. Flow Cytometry. Humans. Male. Middle Aged. Predictive Value of Tests. Reproducibility of Results. Stem Cells / metabolism. Stem Cells / pathology

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15085760.001).
  • [ISSN] 0001-5547
  • [Journal-full-title] Acta cytologica
  • [ISO-abbreviation] Acta Cytol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Biomarkers, Tumor
  •  go-up   go-down


89. Nagasaki A, Miyagi T, Nakazato T, Taira N, Ohshima K, Kikuchi M, Takasu N, Masauda M: Very late central nervous system relapse in a patient with B cell lymphoblastic lymphoma. Acta Haematol; 2004;112(4):212-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Very late central nervous system relapse in a patient with B cell lymphoblastic lymphoma.
  • Very late relapse of lymphoblastic lymphoma (LBL) is very rare.
  • We report a case of a patient who developed central nervous system (CNS) relapse of LBL 16 years after the onset of the primary disease.
  • An 8-year-old girl was hospitalized with a skin tumor in the occipital region on November 27, 1984.
  • Examination of a biopsy of the skin tumor showed typical features of non-Hodgkin's lymphoma (diffuse medium-sized cell type).
  • She received multiagent chemotherapy and went into remission.
  • A midline suboccipital craniotomy was performed and pathological examination revealed a diffuse proliferation of lymphoid cells, which were positive for terminal deoxynucleotidyl transferase, but negative for CD45RO, CD3 and CD20.
  • Thus, the original diagnosis of diffuse medium-sized lymphoma was revised to B cell LBL.
  • After salvage chemotherapy, the patient underwent high-dose chemotherapy with autologous peripheral blood stem cell support and subsequent craniospinal irradiation.
  • [MeSH-major] Central Nervous System Neoplasms / secondary. Lymphoma, B-Cell / pathology
  • [MeSH-minor] Cell Proliferation. Child. Combined Modality Therapy. Female. Humans. Immunophenotyping. Magnetic Resonance Imaging. Neoplasm Invasiveness. Peripheral Blood Stem Cell Transplantation. Recurrence. Salvage Therapy. Skin Neoplasms / pathology. Skin Neoplasms / therapy. Transplantation, Autologous

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2004 S. Karger AG, Basel.
  • (PMID = 15564734.001).
  • [ISSN] 0001-5792
  • [Journal-full-title] Acta haematologica
  • [ISO-abbreviation] Acta Haematol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


90. Burkhardt B, Reiter A, Landmann E, Lang P, Lassay L, Dickerhoff R, Lakomek M, Henze G, von Stackelberg A: Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group. J Clin Oncol; 2009 Jul 10;27(20):3363-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome for children and adolescents with progressive disease or relapse of lymphoblastic lymphoma: a report from the berlin-frankfurt-muenster group.
  • PURPOSE: Little is known about the outcome of pediatric patients with lymphoblastic lymphoma (LBL) who suffer from progressive disease or relapse.
  • PATIENTS AND METHODS: We analyzed the pattern of LBL relapses after current non-Hodgkin's lymphoma Berlin-Frankfurt-Muenster (BFM) frontline therapy between April 1990 and March 2003.
  • Relapse therapy was according to acute lymphoblastic leukemia (ALL) -Relapse-BFM protocols or ALL-BFM protocols for high-risk patients.
  • RESULTS: Twenty-eight (11%) of 251 registered patients with precursor T-cell LBL (T-LBL) and six (8%) of 73 patients with precursor B-cell LBL (pB-LBL) suffered from relapse.
  • Of the 28 patients with T-LBL, one died from infection during relapse chemotherapy, 18 failed to achieve stable remission and died from disease progression, and nine reached allogeneic stem-cell transplantation (SCT).
  • These four patients are in second remission of their lymphoma for 48, 68, 125, and 131 months, respectively, after allogeneic SCT.
  • One of the four patients developed colon adenocarcinoma 47 months after SCT.
  • Of the six patients with pB-LBL who experienced relapse, one patient died as a result of toxicity of relapse chemotherapy, two died from disease progression after chemotherapy, and three received allogeneic SCT.
  • CONCLUSION: Using modern conventional therapy in the frontline treatment of LBL, 10% of patients suffer from progressive disease or relapse.
  • Because of the extremely poor reinduction success, the salvage rate for these patients is poor, with only a 14% (SE = 6%) overall survival.
  • [MeSH-major] Precursor B-Cell Lymphoblastic Leukemia-Lymphoma / therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Analysis of Variance. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Disease Progression. Female. Germany. Humans. Kaplan-Meier Estimate. Male. Multicenter Studies as Topic. Prognosis. Recurrence. Stem Cell Transplantation / adverse effects. Stem Cell Transplantation / methods. Switzerland. Transplantation, Homologous. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19433688.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Mottl H, Bajciova V, Nemec J, Al Shemmari S, Al Awadi S: High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait. Pediatr Hematol Oncol; 2003 Mar;20(2):103-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High survival rate in childhood non-Hodgkin lymphoma without CNS involvement: results of BFM 95 study in Kuwait.
  • Non-Hodgkin lymphomas (NHL) in children are the second most common malignant tumors in Kuwait.
  • Five children were treated by NHL BFM 90 protocol, 7 pts received NHL BFM 95 scheme, and 9 children underwent therapy abroad or according to different types of protocols.
  • Seven patients diagnosed with NHL--group B: 3 children with Burkitt lymphoma (B-cell NHL) and group A: 4 children with lymphoblastic lymphoma (T-cell NHL)--were treated from October 1995 to September 2000 in the Kuwait Cancer Control Centre according to NHL BFM 95 protocol.
  • Group B consisted of 2 girls and 1 boy; median age at diagnosis was 4 years 8 months, 2 pts classified as stage II and 1 pt as stage III.
  • Group A included 1 girl and 3 boys; median age at diagnosis was 5 years 8 months, 1 pt classified as stage III and 3 pts as stage IV.
  • In group B all 3 pts are in 1st CR; in group A 3 pts are in 1st CR and 1 pt having Li-Fraumani syndrome died after the 3rd relapse of disease during therapy.
  • Treatment results of NHL BFM 95 study in our small group of patients are very optimistic.
  • [MeSH-major] Lymphoma, Non-Hodgkin / mortality
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Asparaginase / administration & dosage. Burkitt Lymphoma / drug therapy. Burkitt Lymphoma / mortality. Burkitt Lymphoma / surgery. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Female. Follow-Up Studies. Humans. Ifosfamide / administration & dosage. Infant. Kuwait / epidemiology. Leucovorin / administration & dosage. Lymphoma, B-Cell / drug therapy. Lymphoma, B-Cell / mortality. Lymphoma, B-Cell / surgery. Lymphoma, T-Cell / drug therapy. Lymphoma, T-Cell / mortality. Lymphoma, T-Cell / surgery. Male. Mesna / administration & dosage. Methotrexate / administration & dosage. Neoplasm Staging. Prednisolone / administration & dosage. Prednisone / administration & dosage. Survival Rate. Thioguanine / administration & dosage. Treatment Outcome. Vincristine / administration & dosage


92. Battaglia F, Uro-Coste E, Delisle MB, Tannier C: [Radiation-induced cavernoma: two cases]. Rev Neurol (Paris); 2008 May;164(5):468-71
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Cavernomes radio-induits. A propos de deux cas.
  • Only a few cases of cavernomas induced by radiation treatment, 78 patients, have been reported in the literature.
  • Medulloblastoma, glioma and acute lymphoblastic lymphoma are commonly diagnosed and treated in childhood, generally in males.
  • We report new cases of cavernomas induced by radiation treatment.
  • The first case was a 55-year-old man given radiation and chemotherapy for frontal astrocytoma at the age of 46.

  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18555880.001).
  • [ISSN] 0035-3787
  • [Journal-full-title] Revue neurologique
  • [ISO-abbreviation] Rev. Neurol. (Paris)
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


93. Rujirojindakul P, Kayasut K, Rohitoprakarn M, Lekhakula A: A unique case of transient spontaneous regression complicated with tumor lysis syndrome of T-cell lymphoblastic lymphoma in HIV-infected patient without antiretroviral therapy. J Med Assoc Thai; 2007 Sep;90(9):1930-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A unique case of transient spontaneous regression complicated with tumor lysis syndrome of T-cell lymphoblastic lymphoma in HIV-infected patient without antiretroviral therapy.
  • Spontaneous regression in high-grade non-Hodgkin lymphoma is rare.
  • Without any steroid or chemotherapy, both clinical and laboratory abnormalities were spontaneously returned to normal limits.
  • However, three weeks later he developed generalized lymphadenopathy.
  • A submandibular gland biopsy revealed to be T-cell lymphoblastic lymphoma.
  • At this time, he was treated with cyclophosphamide, adriamycin, vincristine, and prednisolone (CHOP) with whole brain irradiation.
  • During seven months of chemotherapy, the physical examination and blood chemistry were normal.
  • [MeSH-major] HIV Infections / complications. Precursor Cell Lymphoblastic Leukemia-Lymphoma / etiology. Remission, Spontaneous. Tumor Lysis Syndrome / etiology
  • [MeSH-minor] Adult. Anti-Retroviral Agents. Fatal Outcome. Humans. Male. Meningitis. Time Factors

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - HIV.
  • MedlinePlus Health Information. consumer health - HIV/AIDS.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17957940.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Anti-Retroviral Agents
  •  go-up   go-down


94. Sadruddin S, Medeiros LJ, DeMonte F: Primary T-cell lymphoblastic lymphoma of the cavernous sinus. J Neurosurg Pediatr; 2010 Jan;5(1):94-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary T-cell lymphoblastic lymphoma of the cavernous sinus.
  • The rare occurrence of T-cell lymphoblastic lymphoma as a primary tumor in the cavernous sinus is described.
  • Rapid progression of symptoms led to open biopsy, and a diagnosis of T-cell lymphoblastic lymphoma was made.
  • The patient promptly underwent aggressive chemotherapy in which a modified hyper-cyclophosphamide, vincristine, and dexamethasone without doxorubicin regimen with concurrent radiotherapy was used.
  • The patient achieved complete remission and is currently completing the 2-year maintenance phase of chemotherapy.
  • [MeSH-major] Cavernous Sinus. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis
  • [MeSH-minor] Adolescent. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Dexamethasone / administration & dosage. Diagnosis, Differential. Doxorubicin / administration & dosage. Female. Humans. Radiotherapy, Adjuvant. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043743.001).
  • [ISSN] 1933-0715
  • [Journal-full-title] Journal of neurosurgery. Pediatrics
  • [ISO-abbreviation] J Neurosurg Pediatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; CVAD protocol
  •  go-up   go-down


95. Kahwash SB, Qualman SJ: Cutaneous lymphoblastic lymphoma in children: report of six cases with precursor B-cell lineage. Pediatr Dev Pathol; 2002 Jan-Feb;5(1):45-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cutaneous lymphoblastic lymphoma in children: report of six cases with precursor B-cell lineage.
  • Precursor B lymphoblastic lymphomas (B-LBL) are generally rare, but appear to have a higher incidence in children than in adults.
  • Three occurred in the scalp, one in the skin of the thigh, one in the skin of the face and breast, and one in the subcutaneous tissue of the orbit.
  • None of the cases had bone marrow involvement, while two had bone involvement (maxilla, distal tibia, and distal humerus in one case, and distal tibia and orbital bone in another case); only one case had lymphadenopathy (retroperitoneal).
  • Cases in which cell marker studies by flow cytometry were performed showed positivity for CD10, CD19 with negative CD20, pan-T-cell, and myeloid markers.
  • The five patients who received multiagent chemotherapy are alive with follow-up intervals of 2 to 18 years.
  • Two patients had local recurrences and were given radiation therapy (one with repeating multiagent chemotherapy).
  • One patient (diagnosed in 1962) died of disseminated disease; she had been treated with radiation therapy and 6MP only.
  • Cutaneous B-LBL must be included in the differential diagnosis of small blue cell tumors, especially in children.
  • In contrast to its T-cell counterpart, B-LBL occurs more frequently in females, tends to present as skin or bone lesions, and is associated with a potential cure, even in cases that relapse.
  • [MeSH-major] Lymphoma, B-Cell / pathology. Precursor Cell Lymphoblastic Leukemia-Lymphoma / pathology. Skin Neoplasms / pathology
  • [MeSH-minor] Adolescent. Biomarkers, Tumor / analysis. Child. Child, Preschool. Combined Modality Therapy. Fatal Outcome. Female. Flow Cytometry. Humans. Immunohistochemistry. Neoplasm Proteins / analysis. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11815868.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins
  •  go-up   go-down


96. Qin Y, Shi YK, He XH, Han XH, Zhou SY, Liu P, Yang JL, Yang S, Zhang CG, Dong M, Zhou LQ, Wang JW, Feng FY, Sun Y: [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients]. Zhonghua Zhong Liu Za Zhi; 2009 Jun;31(6):469-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Comparison of the efficiency of CHOP-based regimen with or without high dose consolidation treatment combined with hematopoietic stem cell transplantation in 63 lymphoblastic lymphoma patients].
  • OBJECTIVE: To retrospectively analyze and compare the treatment efficiency of CHOP-based regimens with or without high-dose consolidation treatment combined with hematopoietic stem cell transplantation (HDT-HSCT) in the patients with lymphoblastic lymphoma (LBL).
  • METHODS: From 1989 to 2004, totally 63 patients with LBL were initially treated with a standard CHOP-based regimen.
  • Forty-two of the 63 patients achieved complete response (CR), 26 of those subsequently received consolidation HDT-HSCT, while the other 16 had 6-8 cycles of standard CHOP-based treatment only.
  • RESULTS: Of the 63 patients, 57 had a T-LBL and 6 B-LBL, with a median age of 20 years, 19 (30.2%) had a stage I-II diseases and 44 (69.8%) stage III-IV diseases, 61.9% presented with a mediastinal mass.
  • Of the 42 patients who achieved CR, the 5-year OS rate of the patients who received HDT-HSCT as a consolidation therapy was 59.8% versus 14.6% of the patients treated by CHOP-based regimens alone (P=0.004).
  • Among the 18 patients with bone marrow involvement, 3 received allogeneic HSCT and were all still alive at the follow up time of 22, 32 and 37 months, respectively, while another 4 received auto-HSCT and all died of the disease within 14 months.
  • CONCLUSION: Short term treatment with a CHOP-based regimen is not sufficient for the patients with lymphoblastic lymphoma.
  • High-dose consolidation treatment and hematopoietic stem cell transplantation may improve overall survival and disease free survival.
  • For the patients with bone marrow involvement, allohematopoietic stem cell transplantation is superior to auto-hematopoietic stem cell transplantation.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bone Marrow / pathology. Hematopoietic Stem Cell Transplantation. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Child, Preschool. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Cyclophosphamide / therapeutic use. Disease-Free Survival. Dose-Response Relationship, Drug. Doxorubicin / administration & dosage. Doxorubicin / therapeutic use. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prednisone / administration & dosage. Prednisone / therapeutic use. Remission Induction. Retrospective Studies. Survival Rate. Vincristine / administration & dosage. Vincristine / therapeutic use. Young Adult

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Genetic Alliance. consumer health - Transplantation.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19950562.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Comparative Study; English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; VB0R961HZT / Prednisone; CHOP protocol
  •  go-up   go-down


97. Grenzebach J, Schrappe M, Ludwig WD, Parwaresch R, Zimmermann M, Gadner H, Riehm H, Reiter A, BFM-Group: Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy. Ann Hematol; 2001;80 Suppl 3:B73-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Favorable outcome for children and adolescents with T-cell lymphoblastic lymphoma with an intensive ALL-type therapy without local radiotherapy.
  • In study NHL-BFM 90 we investigated the efficacy of an ALL-type treatment without local radiotherapy for childhood T-cell lymphoblastic lymphoma (T-LBL).
  • From April 1990 to March 1995, 105 evaluable patients, 1.1-16.4 years of age, with T-LBL were enrolled into study NHL-BFM 90.
  • Patients with stage I and II received an 8-drug induction followed by a consolidation including high-dose-methotrexate (MTX) and maintenance therapy up to a total therapy duration of 24 months.
  • Patients with stage III and IV received an additional reinduction and cranial radiotherapy (CRT) (12 Gy for prophylaxis) between consolidation and maintenance.
  • Patients received intensified chemotherapy if tumor regression on day 33 of induction was <70% or when vital residual tumor was present after the induction phase.
  • With a median follow-up of 6.41 years, pEFS at 5 years is 91.4% (SE+/-2.7%).
  • Two patients received intensified therapy due to <70% tumor regression on day 33.
  • Our data demonstrate that, with intensive ALL-type chemotherapy but no local radiotherapy, an event-free survival rate of 90% can be achieved in childhood T-LBL.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lymphoma, T-Cell / drug therapy. Precursor Cell Lymphoblastic Leukemia-Lymphoma / drug therapy
  • [MeSH-minor] 6-Mercaptopurine / administration & dosage. Adolescent. Asparaginase / administration & dosage. Austria. Child. Child, Preschool. Combined Modality Therapy. Cranial Irradiation. Cyclophosphamide / administration & dosage. Cytarabine / administration & dosage. Daunorubicin / administration & dosage. Dexamethasone / administration & dosage. Disease-Free Survival. Doxorubicin / administration & dosage. Drug Administration Schedule. Female. Germany. Humans. Immunophenotyping. Infant. Life Tables. Male. Methotrexate / administration & dosage. Neoplasm Staging. Prednisone / administration & dosage. Radiotherapy, Adjuvant. Remission Induction. Thioguanine / administration & dosage. Treatment Outcome. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • Hazardous Substances Data Bank. CYTARABINE .
  • Hazardous Substances Data Bank. THIOGUANINE .
  • Hazardous Substances Data Bank. DAUNORUBICIN .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. DEXAMETHASONE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. MERCAPTOPURINE .
  • Hazardous Substances Data Bank. PREDNISONE .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • Hazardous Substances Data Bank. METHOTREXATE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11757713.001).
  • [ISSN] 0939-5555
  • [Journal-full-title] Annals of hematology
  • [ISO-abbreviation] Ann. Hematol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] Germany
  • [Chemical-registry-number] 04079A1RDZ / Cytarabine; 5J49Q6B70F / Vincristine; 7S5I7G3JQL / Dexamethasone; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; E7WED276I5 / 6-Mercaptopurine; EC 3.5.1.1 / Asparaginase; FTK8U1GZNX / Thioguanine; VB0R961HZT / Prednisone; YL5FZ2Y5U1 / Methotrexate; ZS7284E0ZP / Daunorubicin; AIEOP acute lymphoblastic leukemia protocol
  •  go-up   go-down


98. Kohli A, Ferencz TM, Calderon JG: Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic lymphoma. Allergy Asthma Proc; 2004 Jul-Aug;25(4):249-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Readministration of high-dose methotrexate in a patient with suspected immediate hypersensitivity and T-cell acute lymphoblastic lymphoma.
  • We developed a high-dose MTX readministration protocol based on a modified, prolonged carboplatin desensitization protocol.
  • MTX readministration was successfully tolerated on three occasions in a 17-year-old male patient with T-cell acute lymphoblastic lymphoma and a history of urticarial reactions to MTX.
  • This high-dose MTX readministration protocol may be valuable for treating patients with T-cell acute lymphoblastic lymphoma and suspected immediate MTX hypersensitivity.

  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • MedlinePlus Health Information. consumer health - Drug Reactions.
  • MedlinePlus Health Information. consumer health - Hives.
  • Hazardous Substances Data Bank. METHOTREXATE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15510585.001).
  • [ISSN] 1088-5412
  • [Journal-full-title] Allergy and asthma proceedings
  • [ISO-abbreviation] Allergy Asthma Proc
  • [Language] ENG
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


99. Schmitz N, Buske C, Gisselbrecht C: Autologous stem cell transplantation in lymphoma. Semin Hematol; 2007 Oct;44(4):234-45
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Autologous stem cell transplantation in lymphoma.
  • High-dose therapy (HDT) followed by autologous transplantation of hematopoietic stem cells (ASCT) is frequently performed in patients with lymphoma.
  • In Hodgkin's disease (HD), HDT/ASCT is a standard indication for patients with chemosensitive first relapse.
  • Patients with indolent or aggressive B-cell lymphoma may benefit from HDT/ASCT if considered as part of first-line therapy or at the time of relapse.
  • However, new randomized studies comparing HDT/ASCT with optimal chemoimmunotherapy are necessary because the introduction of monoclonal antibodies (rituximab) significantly improved the results of conventional chemotherapy.
  • Because data on patients with less frequent entities like mantle cell lymphoma, T-cell lymphoma, Burkitt's lymphoma, or lymphoblastic lymphoma are insufficient, the role of HDT/ASCT needs further study.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Lymphoma / drug therapy. Lymphoma / surgery. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Adolescent. Adult. Antineoplastic Agents / administration & dosage. Burkitt Lymphoma / mortality. Burkitt Lymphoma / therapy. Combined Modality Therapy. Disease-Free Survival. Evidence-Based Medicine. Hodgkin Disease / mortality. Hodgkin Disease / therapy. Humans. Lymphoma, Follicular / mortality. Lymphoma, Follicular / therapy. Lymphoma, Mantle-Cell / mortality. Lymphoma, Mantle-Cell / therapy. Middle Aged. Transplantation, Autologous / utilization. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17961722.001).
  • [ISSN] 0037-1963
  • [Journal-full-title] Seminars in hematology
  • [ISO-abbreviation] Semin. Hematol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 53
  •  go-up   go-down


100. Hoelzer D, Gökbuget N: T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity? Clin Lymphoma Myeloma; 2009;9 Suppl 3:S214-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] T-cell lymphoblastic lymphoma and T-cell acute lymphoblastic leukemia: a separate entity?
  • T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) are considered the same disease, differing by the extent of bone marrow infiltration.
  • Immunophenotypes of T-LBL and T-ALL are identical but differ in frequency, with a higher rate of cortical or mature immunophenotypes in T-LBL, which is probably related to the higher rate (> 90%) of mediastinal tumors.
  • Treatment approaches in T-LBL changed from conventional non-Hodgkin lymphoma (NHL) protocols to intensive NHL protocols but recently to ALL-designed protocols.
  • Mediastinal tumors resolve in most cases of T-ALL with chemotherapy only, whereas in T-LBL additional mediastinal irradiation seems to be beneficial.
  • Strategies for stem cell transplantation (SCT) in T-LBL and T-ALL differ.
  • Autologous SCT in complete remission (CR) in T-LBL gives a 70% survival rate, which is similar to chemotherapy alone.
  • In T-ALL, the subtypes of early and mature T-ALL have a poor outcome with chemotherapy alone (< 30%) and might profit from an allogeneic transplantation in first CR (OS > 50%).
  • MRD may guide further treatment strategies in T-ALL and probably also in T-LBL as indications for a SCT or for the evaluation of novel, particularly T-cell-specific, drugs.
  • [MeSH-major] Precursor Cell Lymphoblastic Leukemia-Lymphoma / diagnosis. Precursor T-Cell Lymphoblastic Leukemia-Lymphoma / diagnosis

  • Genetic Alliance. consumer health - Acute Lymphoblastic Leukemia.
  • Genetic Alliance. consumer health - Lymphoblastic lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19778844.001).
  • [ISSN] 1938-0712
  • [Journal-full-title] Clinical lymphoma & myeloma
  • [ISO-abbreviation] Clin Lymphoma Myeloma
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 39
  •  go-up   go-down






Advertisement